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ABSTRACT OF THE DISSERTATION 
 
 
 
Gut Microbial Taxa and Products that Regulate Immune Responses and Disease Features 
 
by 
 
Yu-Ling Chang 
Doctor of Philosophy in Molecular Biology 
University of California, Los Angeles, 2017 
Professor Matteo Pellegrini, Chair 
 
 
 
Gut microbiome has a profound effect on human health and disease. The burgeoning body 
of research investigating the gut microbiome has illustrated its important roles on not only the 
local inflammatory diseases, such as inflammatory bowel disease, but also on systemic 
immunological disorders, such as autoimmune diseases. Many of these associations were 
determined at the level of metagenome analysis. This provides categorical information on both 
taxonomic composition and predicted functional capacities of the microbial community. This 
thesis tackles the problem of how gut microbiota affect human diseases using both these 
categories of assessment. 
 iii 
Although the accumulating evidence suggested the important roles of gut microbiota in the 
human immune system and Crohn’s disease (CD), the molecular mechanisms of how 
microbiome directly modulates immune responses and leads to CD progression remain unclear. 
To advance the current understanding of microbial roles in CD, we developed a systems biology 
approach to assess the human immune function in response to disease-associated microbial 
products. Progress in computational omics analysis of the microbiome in CD enables the 
functional inference and prediction of microbial metabolites. Both genetic and clinical studies 
suggested the involvement of human CD4+ T cells in CD progression. We therefore tabulated a 
set of microbial metabolites predicted to be differentially abundant in CD, and screened these 
microbial metabolites for their bioactivity in human CD4+ T cell functions. Our screen revealed 
15 bioactive microbial metabolites, 3 previously reported and 12 unprecedented, with selective 
action on CD4+ T cell cytokine production. Mechanistic assessment of one novel microbe-
derived metabolite, ascorbate, revealed apoptosis of activated human CD4+ T cells associated 
with selective inhibition of glycolytic energy metabolism. These findings suggest a substantial 
rate (11%) of bioactive metabolites among the predicted CD-associated metabolite reservoirs 
and provide evidence for novel modes of microbial activity targeting T cell metabolism.  
Emerging studies have characterized the association of taxonomic composition with 
systemic autoimmune diseases with various clinical phenotypes and modes of pathologic 
immune responses. In this thesis, we assessed systemic sclerosis (SSc), a previously unstudied 
autoimmune disease with respect to the microbiome, notable for both systemic manifestations 
and gastrointestinal involvement. The metagenomic study of mucosal-luminal interface (MLI) 
samples revealed a unique microbial composition associated with disease state. Patients with 
SSc had decreased abundances of Faecalibacterium and Clostridium, and increased abundances 
 iv 
of Bifidobacterium, Lactobacillus, Fusobacterium and g-Proteobacteria compared with healthy 
controls. In addition, the increase of Fusobacterium species and the decrease of Bacteroides 
fragilis were associated with moderate/severe gastrointestinal symptoms. We conducted an 
independent study of faecal samples from two independent cohorts of patients, from United 
States and Norway, that revealed a similar group of microbial taxa associations, and a greater 
dysbiosis in patients from the United States. These studies enable the specific targets for 
intervention to avert or treat the gastrointestinal involvement in systemic sclerosis. 
The study of gut microbiota is beginning to evolve from association toward causality. The 
functions of gut microbiota are not only restricted to local inflammatory responses but expanded 
to systemic immune regulations. We hypothesized that gut microbiome may regulate host 
immune cellular responses by producing metabolites.  We investigated the bioactive microbial 
factors regulating Crohn’s disease, and explored the potential microbial taxonomic biomarkers 
in a systemic autoimmune disorder, SSc. Those improved understandings of the microbiome 
activity and metabolism may inform therapeutic strategies and ultimately improve patient health. 
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CHAPTER 1  
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Gut microbiota associated with human health and disease has been appreciated in the past 
decade. It is not surprising that gut microbiota is linked to the local inflammatory conditions in 
the gut, such as irritable bowel syndrome1 and inflammatory bowel diseases(IBD)2. There are 
also intriguing studies identifying the roles of gut microbiota in regulating systemic 
physiological conditions, such as obesity3,4, cardiovascular disease5, and rheumatoid arthritis6. 
Furthermore, the emerging science investigating the gut microbiome highlighted the link of gut-
brain axis leading to major depression7,8 and autism spectrum disorder9,10. Like human genome 
presenting individual identities, gut microbiome becomes the other critical factor to control 
human health.  
Metagenomics analyses impute the potential microbial products 
The human gut is colonized by a remarkably diverse microbial community. The advent of 
high-throughput DNA sequencing technology enables us to assay taxonomic composition and 
understands the whole genome contents for human microbiome11. An important insight is that 
the functional gene profiles predicted from metagenome are relative stable among healthy 
individuals despite highly divergent taxonomic composition12,13. This suggests that the 
functional activity of microbiota is the important indicator for physiological conditions. And, 
that microbial products, the net result of myriad metabolic interactions, could be leading 
mediators through which bacteria dictate disease.  
Computational analyses of metagenome have suggested many ways in which microbiota 
can be associated with diseases; however, this raised an important issue of how to investigate 
the causality and mechanism of disease. Major studies of microbiome research in Crohn’s 
diseases (CD) reported the altered metagenomes associated with CD states, which uncovered 
associations of overall metagenomic diversity and specific metagenes associated with CD, 
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together with the metabolic pathways and predicted microbial products altered in CD (Table. 1-
1)14-16. The fundamental question is whether these observed microbial metabolic pathways are 
the cause of the immunological malfunction and whether there are key microbial products 
driving immune responses. 
The prediction of microbial products from metagenome highly relies on the depth of 
sequencing and the algorithmic approaches to infer the functional and metabolic potentials of a 
microbial metagenome. One intriguing approach is on the concept and bioinformatics 
identification process for bacterial genomic clusters (BGCs), which are the clusters of 
chromosomally adjacent genes encode the enzymes and transporters that are necessary to 
produce and export a specialized metabolite. The prediction uses raw initial shotgun genomic 
sequencing acquisitions to assemble the reference genomic libraries; a PCR-based sequence tag 
approach can be further used to detect known gene clusters17,18. However, community 
metagenomes often comprise short reads from hundreds of different organisms, which are 
relatively challenging to assemble comparing to single-organism genomes19.  
In order to avoid the need for assembly of metagenomic reads, the pipeline of HMP Unified 
Metabolic Analysis Network2 (HUMAnN2) has been introduced to use the current databases of 
orthologous protein family categories20. This computational methodology enabled the efficient 
tool to infer presence/absence and abundance of microbial products in a microbial community 
from metagenome.   
The reservoirs of microbial metabolites 
Understanding the metabolic processes in microbiota enables the better prediction of 
microbial functional capacities from metagenome. The metabolomics measurement of microbial 
metabolites by mass spectrometry and nuclear magnetic resonance allowed the direct evidence 
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of the presence of secreted microbial products. Based on their metabolic processes and pathways, 
the metabolite repertoires of human gut microbiome can be categorized into three groups. 
Primary metabolites are directly produced by the catabolic and anabolic reactions involved 
in cell growth, development, and reproduction. Large portions of these metabolites are either by-
products or intermediates of energy metabolism, which can have a potential to influence host 
energy metabolism. Experimentally, short-chain fatty acids and tryptophan metabolites are the 
primary microbial metabolites reported to affect host biology21,22.  
The second group comprises secondary metabolites, which are not essential to the survival 
of an organism but have a broad spectrum of bioactivities, such as antibiotics, chemotherapeutics, 
or insecticides. The genes encoded enzymes that produce secondary metabolites are identified 
in bacterial genomic clusters (BGCs) which often acquired by horizontal gene transfer. 
Phenazine, for example, is a biologically well-characterized secondary metabolite that plays an 
important role in quorum sensing and biofilm formation in Pseudomonas aeruginosa23,24. 
Several studies developed computational platforms for gene cluster analysis to identify the 
microbial isolates produced phenazine and discover novel phenazine metabolic pathways in 
microbial genomes18,25. The analysis of gene clusters becomes an important bioinformatics tool 
to explore novel isolates produced secondary metabolites and predict the potential architectures 
for host-microbiota interactions26.  
The third group comprises the metabolites of non-microbial origin. These metabolites start 
as host-derived or diet-derived metabolites, which are modified by microbial enzymes in 
mucosal environments such as bile acids27,28, or the small molecules introduced from the external 
environment (exposome) which are chemicals generated through exposure to food, medication, 
or environment29.  
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As the knowledge in microbial metabolites expands, we may ultimately identify metabolic 
biomarkers for diagnostic and develop the novel therapeutic approach. The direct detection of 
metabolites from microbial samples showed that microbial metabolites are remarkably altered 
in CD disease30,31. Alteration of the metabolic profiling at multiple compartments in germ-free 
mice comparing with the wild-type mice suggested the role of gut microbiota influencing 
metabolism in host bodies32. Therefore, it is instructive to focus on microbial metabolites which 
represent the complex functional capacities of microbiota33 and study their direct roles in 
regulating host physiology.  
The bioactive roles of microbial metabolites in host immunity 
Microbial metabolites are believed to be a key class of modulators through which microbiota 
directly interact with the host. Although a handful of bioactive metabolites were reported (Table 
1-2), the large numbers of predicted metabolites suggest that myriad bioactive metabolites 
remain to be discovered11.  
One validated category of microbial metabolites influencing local cellular immune 
functions is short-chain fatty acids (SCFAs). SCFAs are produced by colonic microbiome when 
digesting fiber-containing food34. They are also produced in the process of bacterial 
fermentations or generated as byproducts from nitrogen recycling and amino acids 
metabolisms35. Selective molecules in SCFAs profoundly induced the anti-inflammation, by 
increasing regulatory T cell responses21, inducing anti-inflammatory responses in macrophages 
via the inhibition of histone-deacetylase (HDAC)36. Additional studies demonstrated that SCFAs 
also regulated other non-immune cells, including the suppression of the intestinal epithelial cell 
proliferation37. These data suggested the role of SCFAs in local tissues.  
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As a second molecular class, indole and its metabolites affect both local and remote 
physiological responses. Indole and indole-3-aldehyde (I3A) are catabolized from tryptophan by 
commensal bacteria, Lactobacillus species or Clostridium sporogenes, and both metabolites are 
the agonists for the aryl hydrocarbon receptor (AhR). Through the AhR activity in either 
regulatory T cells or NKp46+ILCs at the mucosal site, indole derivatives can regulate the 
mucosal IL-22 production38. Dietary tryptophan metabolized by gut microbiota was also reported 
to remotely modulate astrocyte activity in CNS39. These studies demonstrated the potential roles 
of gut microbial metabolites in remote or systemic immunological regulations. 
Conclusion 
This introduction conveys how the assessment of host-microbiome physiology is evolving 
from microbial taxonomy to the products of the microbiome. This shift creates the opportunity 
to form mechanistic hypotheses on how the microbiome affects host physiology and disease 
biology.  This thesis reflects this evolution.  
In Chapter 2, we take advantage of a robust, established metagenomics dataset for Crohn’s 
disease, to take up the challenge of assessing microbial function in regulating immune function 
in CD. We hypothesized that there are numbers of unidentified microbial metabolites as 
modulators to regulate host-microbiota interaction and to drive disease progression. The study 
established a novel pipeline for identifying candidate microbial products of the disease-
associated microbiome, and subjecting them to validation of bioactivity in a central host trait of 
CD (CD4+ T cell activation and Th17 induction).  
In Chapters 3 and 4, we studied the association of gut microbiota in a life-threatening and 
previously unstudied immunologic disease, SSc. We believed that gut microbiota may play an 
important role in affecting gastrointestinal tract symptoms in SSc. Understanding the association 
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of gut microbiome with symptoms may suggest the use of either antibiotics or probiotics in SSc 
and ultimately provide better quality of life in patients. The outcomes of these studies each have 
revealed new insights about the gut microbiome in SSc.  
To conclude, this thesis has reinforced the roles of gut microbiota in the human diseases, 
and establishes a generalizable strategy of moving from taxonomic to functional microbiome 
analysis in disease biology. 
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Tables 
Table 1-1. Alteration of microbial metabolic pathways in CD patients versus controls. 
 
Study Cohort Samples Increased in CD Decreased in CD 
Morgan 
et al. 
201214 
PRISM Biopsies Nitrogen metabolism 
Sulfur metabolism 
Fructose and mannose metabolism(iCD) 
Riboflavin metabolism(iCD) 
Bacterial secretion system(iCD) 
Cysteine and methionine metabolism 
(iCD) 
Pentose phosphate pathway(iCD) 
Butanoate metabolism (iCD) 
Lysine biosynthesis 
Tong et 
al. 
201315 
MLI Lavage Oxidative responses 
Glycan metabolism 
Amino acid metabolism 
Gevers 
et al. 
201416 
RISK Biopsies, 
Feces 
Glycan biosynthesis and metabolism 
Glycerophospholipid and 
Lipopolysaccharide metabolism  
 
Amino acid metabolism 
-  Asparagine synthase 
-  Glutamate synthase 
Lipid metabolism 
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Table 1-2. List of experimentally proved bioactive metabolites 
 
Metabolites Microbial genera/species40 Host Cell type/Model 
Molecular target/ 
Mechanism of action Ref 
SCFAs 
Acetate,  
Propionate, 
Butyrate 
Most anaerobic gut 
bacteria studied 
produce acetate 
Human 
 
Primary 
monocytes 
Induce prostaglandin E2 
(PGE-2), cytokine IL-10, 
and chemokine MCP-1 
production 
41 
 
Bacteriodes, 
Ruminococcaceae, 
Lachnospiraceae 
Mouse Treg cells 
Induce the differentiation of 
Treg cells in the colonic 
lamina propria via inhibiting 
histone deacetylases 
21,34 
Butyrate Mouse Macrophages 
Inhibit the pro-inflammatory 
mediators in colon 
macrophages 
36 
 Human Mouse 
Intestinal 
epithelial cells 
Suppress the proliferation of 
epithelial cells  
37 
Indole 
derivatives 
(Trp) 
Indole-3-
aldehyde 
(I3A) 
Lactobacillus Mouse 
Ido1-/- mice 
+dietary sup. with 
Trp  
Induce aryl hydrocarbon 
receptor (AhR)-dependent 
Il-22 transcription 
38 
Indole Lactobacillus, 
Bifidobacterium, 
Bacteroides 
fragilis, 
Parabacteroides, 
Clostridium 
Mouse 
Ido1-/- mice Activate AhR  38 
Colonic L cells 
Modulate the secretion of 
glucagon-like peptide-1 
(GLP-1) 
42 
Indole 
sulfate Human  
THP-1 cells and 
HUVEC cells 
Induce the leukocyte- 
endothelial interaction via 
E-selectin 
43 
Choline 
derivatives 
Trimethyl-
amine 
(TMA), 
Trimethyl-
amine N-
oxide 
(TMAO) 
Faecalibacteriu, 
Bifidobacterium, 
Clostridium, 
Proteus 
Mouse 
Dietary sup. with 
choline or TMAO 
in germ-free mice 
Upregulate the multiple 
macrophage scavenger 
receptors linked to 
atherosclerosis and 
cardiovascular disease 
 
44 
Bile acid 
Cholic 
acid (CA), 
Deoxychol
ic acid 
(DCA) 
Lactobacillus, 
Bifidobacteria, 
Bacteroides, 
Clostridium 
Mouse Germ-free mice Microbial control the pool size of bile acid via FXR 
28 
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CHAPTER 2 
A screen of Crohn’s disease-associated microbial metabolites identifies ascorbate as a novel 
metabolic inhibitor of activated human T cells 
 11 
Abstract 
Microbial metabolites are an emerging class of mediators influencing CD4+ T cell function. To 
advance the understanding of direct causal microbial factors contributing to Crohn’s disease (CD), 
we screened 139 predicted CD-associated microbial metabolites for their bioactivity on human 
CD4+ T cell functions induced by disease-associated T helper 17 (Th17) polarizing conditions. 
We observed 15 metabolites with CD4+ T cell bioactivity, 3 previously reported and 12 
unprecedented. Mechanistic assessment of one novel microbe-derived metabolite, ascorbate, 
revealed apoptosis of activated human CD4+ T cells associated with selective inhibition of 
glycolytic energy metabolism. These findings suggest a substantial rate of relevant T cell 
bioactivity among CD-associated microbial metabolites, and evidence for novel modes of 
bioactivity, including targeting of T cell energy metabolism.  
 12 
Introduction 
 Abnormalities of intestinal microbial composition are strongly associated with inflammatory 
bowel diseases45-47. In the healthy state, much evidence suggests that small molecule products of 
the microbiota (microbial metabolites) are important modulators of normal host physiology33,48,49. 
Among these, the literature includes only a handful of bioactive microbial metabolites, and few 
metabolites directly affect cellular targets of CD relevance21,37. In CD, previous multi‘omic studies 
suggest an association with alteration of microbial energy metabolism, enrichment of 
carbohydrate, lipid, cofactor and vitamin metabolism, and depletion of amino acid 
biosynthesis16,50,51. Certain of these microbial metabolites are known to influence important 
aspects of host metabolism52, activity of intestinal epithelial stem cells37, and regulation of diverse 
immune cellular responses21,34,36. For example, short chain fatty acids (SCFAs) such as butyrate 
are known for their mechanisms of action on immune responses through the inhibition of histone 
deacetylase36. Tryptophan catabolites induce T cell cytokine expression through a process 
involving ligand-activated aryl hydrocarbon receptor, AHR53. However, most inferred microbial 
metabolites remain untested for bioactivity on disease-relevant host responses, and unresolved for 
their mechanisms of action.   
In genetically susceptible individuals, CD results from inappropriate immune responses to the 
unique intestinal microbiota54,55. Functional assessment of CD genetic loci revealed the 
involvement of CD4+ effector T helper signaling and the Th17-IL23 pathway56,57. Both clinical 
studies and pre-clinical colitis studies strongly link Th17 cell responses and the IL-17 pathway to 
the pathogenesis of CD58-62. Given their pathogenic role, Th17 cells became a therapeutic target63, 
but clinical trials revealed unexpected inefficacy and disease exacerbation64-68. Subsequent work 
has uncovered dichotomous roles of the IL-17 pathway in CD progression, reflecting the 
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differential roles of Th17 cells in disease induction and resolution69. This affirms the importance 
of Th17 in CD, but suggests complexity in how the intestinal microbiome and its products may be 
targets and modifiers of mucosal effector T cell function. 
To determine how CD-associated microbiome and its products might modulate CD4+ T cell 
responses, we tabulated a set of microbial metabolites predicted to be differentially abundant in 
CD. We functionally screened these metabolites by adding them to CD4+T cell cultures together 
with Th17-polarizing cytokines. This conceptually recapitulates the in vivo setting, in which 
lymphocytes simultaneously encounter bacterial products and inflammatory cytokines in the sub-
mucosa or draining lymph nodes. Our screen revealed a substantial frequency (11%) of metabolites 
that modulated T cell activity, with different patterns of inhibition and augmentation. Detailed 
study of one microbe-derived metabolite, ascorbate, demonstrated potent inhibition of activated 
effector CD4+ T cells associated with inactivation of glycolytic energy metabolism. These findings 
support the idea that disease-associated microbial metabolites may have a significant role in the 
pathogenesis of CD. 
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Materials and Methods 
Human blood sample collection and T cell isolation  
We recruited healthy donors at UCLA Medical Center, and collected blood samples according to 
an IRB protocol approved by the institutional review committee of University of California, Los 
Angeles. Human CD4+ T cells were isolated using Rosettesep Human CD4+ T cell enrichment 
cocktails (StemCellTM technology) following manufacturer’s instructions. Purified CD4+ T cells 
were confirmed to be > 95% pure by flow cytometry and the T cell subset composition was 
monitored (Figure S4-1). We cultured T cells with soluble anti-CD28 (0.2 ug/ml) antibodies on 
96-well plates pre-coated with anti-CD3 antibodies (1ug/ml). Interleukin 2 (IL-2) was added at 4.8 
U/ml (2 ng/ml). We induced Th17 differentiation with 50 ng/ml IL-6, 50 ng/ml IL-1b and 50 ng/ml 
IL-23 70. We refed T cells at day 7 with medium containing the same Th17 polarizing cytokines 
and further cultured for another 7 days. We collected supernatants for multiplex Luminex cytokine 
analysis, and analyzed T cells by intracellular flow cytometry. 
Cell survival assay  
The survival of metabolites-conditioned cells was examined by SYTOX™ Red dead cell stain 
(Molecular Probes, Cat.S34859), which is a nucleic acid stain that penetrates cells with 
compromised plasma membranes. We used the SYTOX™ Red dead cell stain after cell surface 
marker staining, and detected SYSTOX Red levels by flow cytometry.  
Intracellular Flow Cytometry 
At the end of the 14-day culture, T cells were stimulated with Leukocyte activation cocktail 
with BD GolgiPlug (BD Biosciences, Cat. 550583) for 4 hours and washed in FACS buffer. 
BV650-conjugated CD3 (Clone OKT3) and PE-CF594-conjugated CD4 (Clone OKT4) antibody 
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were used to detect these cell surface markers. We performed intracellular fixation and 
permeabilization with a commercial buffer set (eBiosciences, Cat. 88-8824). The following 
antibodies were used to detect intracellular cytokines: APC-conjugated IL-17A (Clone 
eBio64DEC17), FITC-conjugated IFNg (Clone 4S.B3), PE-conjugated IL-10 (Clone JES3-9D7), 
and PE-Cy7-conjugated IL-4 (Clone 8D4-8) were purchased from eBioscience or Biolegend).  
Cell respiration measurements 
We activated isolated CD4+ T cells on plates coated with 10 ug/ml anti-CD3 and 10ug/ml 
anti-CD28, and stimulated in the presence of 10 ng/ml IL-2 as the activated condition, and 10 
ng/ml IL-7 as the resting condition. After 48 hours, activated or resting cells were collected, 
washed with unbuffered DMEM (2 g/L glucose), and seeded into 0.2% gelatin-covered 24-well 
plates (XF24 from Seahorse) (1 million cells/well) for OCR and ECAR measurement. We 
measured cellular OCRs and ECARs as described previously71. Oxygen consumption was blocked 
by oligomycin (0.75 uM), an ATP synthase inhibitor; the ionophore FCCP (carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone; 1uM) assayed maximal respiratory capacity of mitochondria, 
whereas rotenone (3 uM), a mitochondrial inhibitor, was used to block mitochondrial respiration. 
Two independent experiments were performed, and 6 technical replicates per experiment were 
measured to calculate the mean ± SEM for each time point.  
Bioinformatic prediction of CD-associated microbial metabolites. 
Using a previously reported PRISM dataset14 of microbial composition at the level of OTUs 
from 16S rRNA gene amplicon sequencing data, we tabulated microbial count data for healthy and 
CD subjects at the subject level, and converted them to imputed metagene data using PICRUSt11. 
We then determined the relative abundance of enzymatic pathways using HUMAnN220, with 
pathway end-products identified using UniRef and MetaCyc databases. Making the assumption 
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that metabolite abundance is the sum of abundances of the generating enzymes, we calculated the 
predicted abundance of each metabolite using the average of most abundant route through each 
pathway. 
Disease-associated metabolites were determined using a multivariate model comparing 
predicted relative compound levels in health versus CD subjects. Specifically, we performed a 
generalized linear mixed model (glmmPQL, implemented in R), correcting for age and 
medications (antibiotics, immunosuppressants and anti-inflammatory agents).  Disease-associated 
metabolites from this analysis were ranked by multi-testing corrected q value. From this raw list, 
the top molecules for which commercial sourcing could be identified were tabulated (Table S2-1), 
and procured for testing.   
For prediction of ascorbate-producing microbiota, we used the reverse of this bioinformatics 
pipeline, with the following modifications. Microbial metabolic pathways and enzymes involved 
in ascorbate biosynthesis were defined using KEGG and literature reports. For those enzymes 
annotated in KEGG or MetaCyc databases, we performed a prediction of microbiota genomically 
bearing them using PICRUSt-precalculated gene content. We filtered these results for human 
fecal-associated OTUs, generating lists of OTUs bearing various numbers of ascorbate pathway 
genes. Finally, we filtered for OTUs validated for significant differential association in CD 
versus healthy subjects. 
The computational resources for all analytic steps are available at 
https://bitbucket.org/biobakery/biobakery/wiki/Home.  
Metabolite preparation 
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All chemical were of cell culture or higher grade, and purchased from Sigma Aldrich. The 
majority of chemicals were dissolved in aqueous solution; water-insoluble metabolites were 
dissolved in DMSO. 
Luminex multiplex cytokine production 
We measured cytokines from CD4+ T cell culture supernatants using Luminex. The following 
11 cytokines were included in the Luminex panels and acquired on a Luminex® FLEXMAP 3D: 
Th17 cytokines, IL-17A, IL-17F, and IL-22; Th1 cytokines, TNFa and IFNg; and Th2 cytokines, 
IL-5 and IL-13; Treg cytokine, IL-10; other related cytokines, IL-9, IL-21, and MIP-3a. We 
normalized the Luminex readouts for the cell count values.  
Detecting ascorbate in bacterial culture 
Pseudomonas aeruginosa included two strains, PA-01 and PA-14, obtained from the ATCC. 
Burkholderia cepacia included three clinical isolates (2-1, 3-1, 3-2; source strains ZK2853-
ZK2862) from two cystic fibrosis patients72, a gift from the collection of Robert Kolter (Harvard 
Medical School). Bacteria were cultured in 1 mL Luria-Bretani broth at 35 ± 2oC  under aerobic 
condition, and the bacterial cell numbers were monitored by McFarland standard 73. After pelleting 
bacterial cells (5,000 rpm, 10 min), we filtered the supernatants using centrifugal filters per 
manufacturer instructions (Corning® Costar® Spin-X® centrifuge tube filters, 0.22µm). We 
measured ascorbate levels in supernatant filtrates by an enzyme-based assay (Abcam, ab65656).  
Statistical analysis 
To estimate contributors of experimental variability and control for potential technical effects, 
we performed principal variance component analysis (PVCA). The technical factors assessed 
included metabolite, experimental run, donor, and technical replicates in different plates. We used 
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PCA to reduce data dimensionality data from the 11 cytokines, and to maintain majority of the 
variability in the data. We used VCA to fit a mixed effect model using subject-specific factors as 
random effects to estimate and partition the total variability. Figure S2-3 shows one example. We 
ran PVCA for every experiment to ensure the stability of technical variation.   
We used multivariate analysis of variance (MANOVA) to identify putative bioactive 
metabolites. In each condition treated with a specific metabolite concentration, we compared the 
levels of the 11 cytokines to those found in the vehicle control condition. We defined a metabolite 
as bioactive if p-values < 0.05; we confirmed bioactivity in a different healthy donor to confirm 
metabolite bioactivity.  
To further validate biological effects and define specific cytokine responses to bioactive 
metabolites, we employed two-way analysis of variance (ANOVA) with metabolite and donor 
factors using the incorporated data from at least two independent experiments. We used the Holm-
Sidak’s post-test to correct for multiple comparisons. We defined statistical significance as 
adjusted p-values < 0.05.   
We generated cytokine heatmaps from Luminex cytokine data by calculating the mean of log2 
fold change between metabolite-untreated versus metabolite-treated samples (treated/untreated). 
We used the heatmap.2 function in gplot package to generate dendrogram and colorplot in R 
version 3.2.4.  
We performed statistical analyses with Prism software (GraphPad) or using the R program (R 
version 3.1.1). We used the nonparametric Mann-Whitney test to compare two experimental 
conditions. We defined statistically significant results are indicated (*p < 0.05, ***p <0.001). We 
displayed error bars using mean ± SEM calculated from 3 or more experimental replicates. 
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Results 
Screening of microbial metabolites identifies modulators Th17 responses 
We identified a panel of fecal microbial metabolites predicted to be differentially produced 
by a CD-associated versus healthy microbiome using the previously reported PRISM cohort14 (see 
Materials and Methods). From this panel, we selected a subset of 139 commercially available 
metabolites for further testing (Table S2-1).  In Figure 2-1a, we summarize the workflow for the 
bioactivity screen of these metabolites on human Th17 polarization cultures. Briefly, purified 
human blood CD4+ T cells were cultured with different concentrations of each metabolite in the 
presence of standard 14 day Th17 polarization culture conditions (anti-CD3, anti-CD28, IL-6, IL-
1β, and IL-23)70. We assessed Th17 polarization by levels of secreted cytokines, and validated by 
the percentage of Th17 cells by flow cytometry (Figure S2-2).  
We first qualitatively and quantitatively screened for metabolite conditions that caused 
toxicity by the endpoints of cell death and reduced cell numbers. We tabulated metabolite 
conditions that significantly increased toxicity, and excluded them from downstream cytokine 
analyses. Notably, we did not observe any metabolites that significantly enhanced cell numbers 
(data not shown).  
The primary screening revealed eighteen bioactive metabolites based on a relaxed cut-off in 
multivariate analysis of variance (Figure 2-1b). We performed a confirmatory screening in 
independent healthy individuals to validate the primary screen and refine dose-dependent 
responses (two-way ANOVA). Figure 2-1c summarizes results for all screened metabolites with 
respect to toxicity and secreted cytokine production. Principal variance component analysis 
(PVCA) demonstrated that the majority (57%) of variability was contributed by metabolite 
treatment, while only 10% of variability was attributed to a donor effect (Figure S2-3). Sixteen 
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metabolites (11%) were toxic based on cell death at all tested conditions in both donors. A total of 
fifteen metabolites (11%) displayed reproducible effects on T cell cytokine production, and were 
classified as validated bioactive. Three metabolites (2%) showed inconsistent cytokine changes 
between two individual experiments, and were classified as putatively bioactive. 
Differential metabolite effects on T cell cytokine profiles 
The fifteen validated bioactive metabolites varied in their pattern of effects on cytokine 
production (Table 2-1). Three of these metabolites were previously reported for analogous effects 
on T cells34,74,75. Our findings confirmed that glutamate enhances IFNg production, butyrate 
inhibits IL-17A but increases IL-10 production, and arachidonic acid inhibits IFNg production 
(Figure S2-4). Strikingly, the action of the other twelve metabolites are unprecedented, to our 
knowledge, for an effect on T cell cytokine production. 
We observed distinct patterns of altered cytokine production. Some metabolites induced 
global changes in cytokine production. GDP-mannose decreased the production of eight cytokines 
(pan-inhibition) at the dose range of 0.1 to 1 mM (Figure 2-2a). Three other metabolites (HMG-
CoA, CoA, and mevalonate) similarly decreased the production of all tested cytokines at high 
concentration (Figure S2-5a). Instead of pan-inhibition, L-homocysteine (1 mM) augmented 
production of most tested cytokines (Figure S2-5b).  
Other metabolites showed selective effects on Th17 cytokines. For example, ascorbate 
decreased Th17-related cytokine production (Figure 2-2b), whereas there was no statistically 
significant change for IL-10, IL-5, and IL-13 production with ascorbate treatment. Three 
metabolites at indicated conditions (0.1 mM glutaryl-CoA, 1mM hexanoyl-CoA, and 1 mM 
isopentenyl diphosphate) enhanced the production of IL-17A and IL-17F (Figure S2-6a).  Other 
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metabolites selectively altered production of certain non-Th17 cytokines. Oleic acid and linoleic 
acid increased IFNg in a dose-dependent fashion (Figure 2-2c and 2-2d); In contrast, 0.1 mM 
pyridoxine phosphate decreased the production of TNFα, IFNγ, and IL-10 (Figure S2-6b).  
Figure 2-2e summarizes the relative cytokine secretion for the twelve novel bioactive 
metabolites. Unsupervised hierarchical clustering classified the metabolites into patterns of 
inhibitory and augmented responses. Among them, six metabolites are fatty acid intermediates or 
end products based on the Human Metabolome Database (HMDB). Ascorbate is the only microbe-
derived metabolite that humans cannot synthesize, which drew our attention to this metabolite for 
deeper validation and mechanistic assessment.  
Ascorbate inhibits T cell cytokines in both polarized and non-polarized conditions 
To further validate ascorbate bioactivity under Th17 polarizing conditions, we performed 
four additional biological replicates, and found that ascorbate consistently inhibited the production 
of Th17 cytokines. Flow cytometry analysis demonstrated that ascorbate induced a dose-dependent 
reduction in IL-17A-producing CD4+ T cells, including both IL-17A single positive T cells and 
IFNγ/IL-17A double positive cells (Figure 2-3a). Measurement of cytokine secretion by Luminex 
confirmed the ascorbate inhibitory effect. All the cardinal Th17 cytokines (IL-17A, IL-17F and 
IL-22) were reduced by more than 50% after 100 uM ascorbate treatment (Figure 2-3b). These 
data confirm that ascorbate inhibits the production of Th17 and Th17-related cytokines under 
Th17-polarizing conditions.  
To investigate whether this inhibiting effect was specific to the Th17 subset, we cocultured 
CD4+ T cells with ascorbate under non-selective activating conditions (anti-CD3/CD28 without 
Th17-polaring cytokines (Figure 2-3c). In the presence of ascorbate, IFNg, IL-4, and IL-17A- 
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producing CD4+ T cells were all reduced, whereas IL-10 producing cells were preserved. Both 
IL-17A-single positive cells and IFNg/IL-17A-double positive cells were reduced in the presence 
of ascorbate. We concluded that ascorbate not only inhibited Th17 cells, but also reduced the 
activation of most other subsets of effector T cells (excluding IL-10-producing T cells).  
Ascorbate selectively inhibits activated but not resting CD4+ T cells. 
       We next determined whether ascorbate regulated all CD4+ T cells, including resting T cells 
and activated T cells. We cultured CD4+ T cells in resting and activating conditions for 48 hours 
in the absence or presence of 100 uM ascorbate. Ascorbate selectively inhibited the upregulation 
of the activation marker CD154 in activating conditions (Figure 2-4a and 2-4b). AnnexinV and 7-
AAD staining further demonstrated that activated but not resting T cells underwent programmed 
cell death after 48 hours of ascorbate treatment (Figure 2-4c). These data illustrated that ascorbate 
selectively inhibited activated versus resting T cells.    
Ascorbate selectively inhibits glycolysis-dependent energy production in activated T cells 
To study the molecular mechanisms involved in ascorbate-induced inhibition, we focused our 
analysis on the regulation of energy metabolic pathways. It is well known that TCR activation, 
specifically CD28 signaling, directly controls the metabolic switch to glycolysis by up-regulating 
the expression of glucose transporter 1, and remodeling activity of downstream biochemical 
pathways to favor glycolytic versus oxidative phosphorylation energy production 71,76,77. In 
contrast, resting CD4+ T cells rely on fatty acid oxidation to generate energy through oxidative 
phosphorylation76. Since glucose transporter 1 (a transporter for the oxidized form of ascorbate) is 
up-regulated in activated T cells71, we reasoned that an increased level of ascorbate is selectively 
transported in activated versus resting T cells. We therefore tested the possibility that ascorbate 
might selectively inhibit glycolysis-dependent activated T cells.  
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Consistent with previous reports, we observed that activated T cells augment their glycolysis 
compared to resting T cells, demonstrated by a significant increase in extracellular acidification 
rate (ECAR) (Figure 2-4d). Upon ascorbate treatment, we observed a significant reduction in 
ECAR by activated but not resting T cells, indicating that ascorbate decreased the glycolytic rate 
in activated T cells (Figure 2-4d and 2-4e). These data support the prediction that a selective 
inhibitory effect of ascorbate on activated T cells was related to its effect on glycolytic energy 
metabolism.  
Ascorbate production by microbial taxa associated with CD  
To investigate whether gut microbes can produce ascorbate, we performed a reverse 
metagenomic search for the bacterial genomes that contained ascorbate biosynthesis enzymes. The 
metabolic pathways utilized by microbes to produce ascorbate de novo are largely unknown, but 
biotechnology has suggested two microbial pathways to manufacture L-ascorbate from D-
glucose78. We therefore investigated the chemical reactions in these processes, and tabulated the 
metabolic enzymes and corresponding metagenes involved in ascorbate synthesis reactions. Using 
this tabulation, we performed a reverse metagenomics search of human fecal microbiota bearing 
some or all of the genes in the archetypal D-sorbitol and 2,5-diketo-D-gluconic acid pathways of 
ascorbate biosynthesis (Table S2-2 and S2-3). We identified 5 Operational Taxonomic Units 
(OTUs) bearing the ascertainable metagenes of the D-sorbitol pathway, all of them in the CD-
associated genus Burkholderia (Figure 2-5a). We also identified 120 OTUs for the 2,5-diketo-D-
gluconic acid ascorbate pathway; of these, the most prevalent taxa belonged to the CD-associated 
genera Pseudomonas and Erwinia (Figure 2-5b). To directly assess ascorbate production by these 
microbes, we assembled a collection of three clinical isolates of Burkholderia and two strains of 
Pseudomonas aeruginosa. After aerobic culture to stationary phase, ascorbate production was 
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detectable in both Pseudomonas strains (Figure 2-5c), but not in the Burkholderia isolates (data 
not shown). These findings indicate that certain CD-associated microbiota are proficient at 
ascorbate biosynthesis, and point to the 2,5-diketo-gluconic acid pathway as a potential mechanism 
for this production.  
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Discussion 
By screening microbial metabolites using primary human CD4+ T cells in Th17 polarizing 
culture conditions, we identified three known and twelve novel microbial metabolites with the 
potential to module T cell cytokine production. A detailed study of one novel microbial-derived 
metabolite, ascorbate, revealed inhibition of Th17 and activated T cell formation by a mechanism 
involving blockade of glycolytic energy metabolism. We metagenomically inferred and 
functionally validated examples of CD-associated microbiota proficient for ascorbate production. 
These findings suggest a substantial frequency of relevant T cell bioactivity among CD-associated 
microbial metabolites, and evidence for novel modes of bioactivity, including targeting of T cell 
energy metabolism. 
This study emphasizes the importance of environmental metabolic cues to modulate CD4+ 
T cell functions, notably via differentiation and activation of specific subsets of CD4+ T cells with 
distinct cytokine expression patterns79,80. Three bioactive metabolites identified in our study 
confirmed previous observations of these metabolites as selective mediators of such differentiation 
and activation34,74,75. The bioactivity of twelve additional metabolites for human CD4+ T cells did 
not have literature precedents to our knowledge. The diversity of their effects on T cell cytokine 
function suggests that their mechanistic assessment may reveal new insights on the action of 
microbial metabolites in CD4+ T cell function, and the role of these actions in disease biology. 
This study uncovered a previously unknown inhibitory action of ascorbate on activated 
CD4+ T cells. A recent report demonstrated that ascorbate selectively kills glycolysis-dependent 
cells (epithelial carcinoma) by its inactivation of glyceraldehyde 3-phosphate dehydrogenase, an 
apex enzyme in glycolytic energy metabolism81. The present study confirmed the selective effect 
of ascorbate on glycolytic energy production, and extended the observation to the CD4+ T cell 
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type. It is well known that the early phase of T cell activation induces a metabolic switch to and 
dependence upon aerobic glycolysis71,76,77. This provides a plausible mechanism by which 
ascorbate, via interruption of glycolytic energy production, may account for the selective 
functional inhibition and apoptosis of activated CD4+ T cells. However, a recent report observed 
that after completion of Th17 induction, these cells shift again to oxidative phosphorylation as 
their preferential energy source82. These findings suggest that the potential in vivo action of 
ascorbate on Th17 cells may be limited to the stages of Th17 induction and activation, and to their 
relevant anatomic sites (such as mesenteric nodes in the case of intestinal Th17 cells).  
We also observed that ascorbate inhibits the production of IFNg-, IL-4, and IL-17A, but not 
IL-10. Unlike other CD4+ T cell subsets, induced Tregs (which inhibit effector T cell responses in 
part through IL-10 release) do not substantially shift to glycolytic energy metabolism76,77, and this 
may account for their resistance to ascorbate inhibition. Moreover, in mice ascorbate facilitates the 
demethylation of Foxp3 enhancer and promotes Treg cell function83,84. Taken together, these 
observations suggest that ascorbate as an environmental cue that may selectively inhibit effector 
CD4+ T cell responses.  
An issue raised by these observations is the physiological role of dietary ascorbate versus 
local microbial ascorbate production. Unlike most eutherians, humans and primates require 
ascorbate intake, because they genetically lack the enzyme responsible for the last step in ascorbate 
synthesis, L-gulonolactone oxidase85.  Previous work indicates that microbial ascorbate is not the 
major nutritional source for vitamin C in humans86, suggesting the importance of dietary intake of 
ascorbate in human. However, dietary ascorbate is largely absorbed before transit to the colon, so 
local microbial production may be a significant contributor to luminal ascorbate in the distal 
intestine. The predicted ascorbate-producing genera are Proteobacteria, an uncommon intestinal 
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phylum most prevalent in the colon. Pseudomonas aeruginosa and related species are notable for 
their production of redox-active small molecules that modify the cellular redox state, acting as 
inter-microbial signals to control biofilm formation23. Ascorbate may represent an additional class 
of redox-active molecules involved in such inter-microbial interaction. Microbial genetics and 
ecologic studies are necessary to assess the control and bioavailability of ascorbate in the gut, and 
test its potential role in microbial ecology.  
Clinically, ascorbate levels and the ratio of oxidized form (dehydroascorbic acid, DHA) 
versus reduced form (ascorbic acid, AA) of ascorbate are distinct in IBD patients versus healthy 
subjects 87. Genetic variations in the sodium-dependent ascorbate transporter gene, SLC23A1, have 
been significantly associated with susceptibility to CD 88. The disease variant of human SLC23A1 
results in lower transporter activity and decreased intracellular ascorbate. Decreased ascorbate 
transport limits the capacity to prevent oxidative tissue damage and impair recovery from mucosal 
injury 89. However, the mechanistic basis of these disease-associated phenotypes has not yet been 
probed in experimental animal models, because except for primates, eutherians are proficient for 
ascorbate synthesis. Such studies, and testing the potential in vivo roles of microbial ascorbate on 
CD4+ T cells and CD, await genetic engineering of mice bearing the human-homologous L-
gulonolactone oxidase deficiency.   
Collectively, we screened a panel of predicted CD-associated microbial metabolites and 
identified 12 novel and 3 proven modulators of human CD4+ T cell function. We also 
demonstrated that a novel microbial-derived immune modulator, ascorbate, regulates host 
responses via inhibition of energy metabolism. Our results suggest that the balance of luminal 
metabolites could be important to maintain physiological CD4+ T cell functions of the intestinal 
mucosa. 
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Tables and Figures 
Table 2-1. Validated bioactive metabolites. 
Metabolite Name HMDB_ID Chemical Category (HMDB) 
(S)-3-Hydroxy-3-
methylglutaryl-CoA 
HMDB01375 Fatty Acyls 
Hexanoyl-CoA HMDB02845 Fatty Acyls 
GDP-mannose HMDB01163 Purine nucleotides 
Isopentenyl diphosphate HMDB04196 Prenol lipids 
CoA HMDB01423 Purine nucleotides 
L-Glutamate HMDB00148 Amino acids, peptides, and analogues 
L-Ascorbate HMDB00044 Furanones 
L-Homocysteine HMDB00742 Carboxylic acids and derivatives 
(R)-Mevalonate HMDB59629 Fatty acids and conjugates 
Glutaryl-CoA HMDB01339 Fatty Acyls 
Pyridoxine phosphate HMDB01319 Pyridines and derivatives 
Oleic acid HMDB00207 Fatty Acid 
Arachidonic acid HMDB01043 Fatty Acid 
Linoleic acid HMDB00673 Fatty Acid 
Butyric acid HMDB00039 Fatty Acid 
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Figure 2-1 
 
Figure 2-1. Microbial metabolites screen identifies bioactive metabolites modulating Th17 
responses (a) Schematic of screening and analytic strategies. Toxic: cell death observed at all 
tested conditions; Potential Bioactive: achieved MANOVA statistical significance cut-off; 
Putative Bioactive: significant effects in first round but not second round of screening, potentially 
due to donor-specific variation; Validated Bioactive: reproducible effects in two individuals 
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(achieved statistical significance cut-off by two-way ANOVA test). (b) Aggregate cytokine 
response (negative logarithm of the association p-values calculated from multivariate analysis of 
variance) to candidate metabolites. P<0.0004 represents the significant threshold after Holm-Sidak 
correction for multiple comparisons (Blue dots). (c) Categories of response to metabolites (% of 
all tested metabolites).  
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Figure 2-2 
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Figure 2-2. Representative bioactive metabolites altering CD4+ T cell cytokine secretion. (a) 
Pan-inhibition of cytokine secretion by GDP mannose. (b) Th17-specific cytokine inhibition by 
ascorbate. N.A.: condition that causes cell death and excluded. (c, d) Th1-specific cytokine 
augmentation by oleic acid (c) and linoleic acid (d). For each of the two donors (black and gray), 
we calculated mean ± SEM from three technical replicates. (e) Summary heatmap of multiplex 
cytokine expression data for the 12 novel validated-bioactive metabolites. We show metabolite-
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treated samples (rows) at the optimal bioactive concentration. Asterisks (*) highlight metabolites 
with dose-dependent effects. CoA: Coenzyme A; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-
coenzyme A. Four metabolites with dose-dependent effects are marked with an asterisk (*).  
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Figure 2-3 
 
Figure 2-3. Ascorbate inhibits T cell cytokines in both polarized and non-polarized 
conditions. (a,b) CD4+ T cells were cultured with 0 to 1 mM of ascorbate as described in Figure 
1. (a) Intracellular flow cytometry and (b) Luminex measurement of four biological replicates (four 
colors, mean ± SEM). (c) We cultured CD4+ T cells under T cell activation condition with 0 or 
0.1 mM of ascorbate. We used intracellular flow cytometry to determine the percentages of 
indicated CD4+ T cells. Mean ± SEM calculated from three biological replicates. 
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Figure 2-4 
 
Figure 2-4. Ascorbate selectively inhibits activated but not resting CD4+ T cells.  We cultured 
CD4+ T cells in 10 ng/ml of IL-7 (resting) or activated with 1ug/ml anti-CD3 and anti-CD28 
antibody (activated) for 48 hours. We assessed T cell activation (CD134+) by flow cytometry. (a) 
Representative plot (b) Summary of the three independent experiments.  (c) We measured cell 
death by Annexin V flow cytometry from three independent experiments. (d, e) Seahorse platform 
measurements of OCR and ECAR. (d) Representative plot; (e) Mean ± SEM calculated from 6 
technical replicates.  
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Figure 2-5 
 
Figure 2-5. Gut microbes producing ascorbate. (a) Enzymes involved in the sorbitol pathway 
or (b) in the 2,5-diketo-D-gluconic acid pathway of ascorbate biosynthesis. OTUs: operational 
taxonomic unit. Left: Numbers of OTUs bearing metagenes for the indicated number of pathway 
enzymes. Right: Bar plots of the numbers of OTUs expressing indicated enzymes in bacterial 
genera. (c) We cultured bacteria for 24 hours and then collected supernatants to measure 
ascorbate levels. Since all cultures had reached equivalent McFarland readings at 24 hours, the 
ascorbate levels represent production from comparable cell numbers.  
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Supplementary Tables and Figures 
Table S2-1. List of screened metabolites 
Metabolite Name HMDB_ID KEGG_ID Cat.#  (Sigma-Aldrich) 
L-Phenylalanine HMDB00159 C00079 P5482-25G 
gamma-L-Glutamyl-L-cysteine HMDB01049 C00669 G0903-25MG 
Sulfite HMDB00240 C00094 S0505-250G 
D-Fructose 1,6-bisphosphate HMDB01058 C00354 F6803-1G 
Thiamin monophosphate HMDB02666 C01081 T8637-5G 
(R)-5-Phosphomevalonate HMDB01343 C01107 07841-10MG 
O-Acetyl-L-serine HMDB03011 C00979 A6262-10MG 
L-Lysine HMDB00182 C00047 L5501-10MG 
2-Oxoglutarate HMDB00208 C00026 K1875-1G 
dTMP HMDB01227 C00364 T7004-100MG 
(S)-3-Hydroxy-3-methylglutaryl-
CoA HMDB01375 C00356 H6132-5MG 
beta-Alanine HMDB00056 C00099 A9920-100G 
alpha-D-Glucose 6-phosphate HMDB01401 C00668 G7250-10MG 
Phosphoenolpyruvate HMDB00263 C00074 P7127-100MG 
Glutathione HMDB00125 C00051 PHR1359-500MG 
UTP HMDB00285 C00075 U6875-100MG 
dTTP HMDB01342 C00459 GE27-1880-04 
Hexanoyl-CoA HMDB02845 C05270 H2012-5MG 
D-Fructose 6-phosphate HMDB00124 C00085 F3627-10MG 
2-Dehydro-3-deoxy-D-gluconate HMDB01353 C00204 12271-1MG 
O-Phospho-L-homoserine HMDB03484 C01102 04668-50MG 
Succinate HMDB00254 C00042 W327700-1KG-K 
Glyoxylate HMDB00119 C00048 G10601-25G 
L-Ornithine HMDB00214 C00077 O2375-10MG 
GDP-mannose HMDB01163 C00096 G5131-10MG 
 D-Glyceraldehyde 3-phosphate HMDB01112 C00118 39705-1ML 
IMP HMDB00175 C00130 I4625-5G 
L-Histidine HMDB00177 C00135 H6034-10MG 
Citrate HMDB00094 C00158 W302600-1KG-K 
Adenosine HMDB00050 C00212 A9251-1G 
D-Mannose 1-phosphate HMDB06330 C00636 M1755-10MG 
LL-2,6-Diaminoheptanedioate HMDB01370 C00666 89469-10MG 
Urocanate/4-Imidazoleacrylic acid HMDB00301 C00785 859796-5G 
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Isopentenyl diphosphate HMDB04196 C00129 00297-10MG 
AMP HMDB00045 C00020 01930-5G 
CoA HMDB01423 C00010 C4282-10MG 
UDP HMDB00295 C00015 94330-100MG 
L-Glutamate HMDB00148 C00025 G1501-100G 
Glycine HMDB00123 C00037 G7126-100G 
L-Arginine HMDB00517 C00062 A5006-100G 
CTP HMDB00082 C00063 C1506-25MG 
Thiamin diphosphate HMDB01372 C00068 C8754-1G 
L-Ascorbate HMDB00044 C00072 A7631-25G/A4034-100G 
L-Methionine HMDB00696 C00073 M9625-5G 
Fumarate HMDB00134 C00122 F1506-25G 
L-Leucine HMDB00687 C00123 L8000-25G 
dATP HMDB01532 C00131 D6500-10MG 
myo-Inositol HMDB00211 C00137 I5125-50G 
L-Homocysteine HMDB00742 C00155 69453-50MG 
Acetoacetate HMDB00060 C00164 A8509-10MG 
Agmatine HMDB01432 C00179 A7127-1G 
D-Glucuronate HMDB00127 C00191 G8645-5G 
Acetyl phosphate HMDB01494 C00227 A0262-500MG 
L-Homoserine HMDB00719 C00263 H6515-10MG 
D-Mannose 6-phosphate HMDB01078 C00275 M3655-100MG 
Creatine HMDB00064 C00300 C0780-10MG 
Isocitrate HMDB00193 C00311 58790-250MG 
L-Citrulline HMDB00904 C00327 C7629-1G 
6-Phospho-D-gluconate HMDB01316 C00345 55962-10MG 
Phosphatidylethanolamine HMDB60501 C00350 1535744-100MG 
cis-Aconitate HMDB00072 C00417 A3412-1G 
(R)-Mevalonate HMDB59629 C00418 50838-10MG 
5,6-Dihydrouracil HMDB00076 C00429 D7628-5G 
dCTP HMDB00998 C00458 D4635-25MG 
Glutaryl-CoA HMDB01339 C00527 G9510-5MG 
Pyridoxine phosphate HMDB01319 C00627 82890-10MG 
(S)-Methylmalonyl-CoA HMDB02310 C00683 M1762-1MG 
Deamino-NAD (NAADP) HMDB01179 C00857 N6506-25MG 
L-Histidinol HMDB03431 C00860 H6647-10MG 
Crotonoyl-CoA HMDB02009 C00877 28007-5MG 
Dephospho-CoA HMDB01373 C00882 D3385-5MG 
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L-Histidinol phosphate  C01100 41486-10MG 
L-Galactono-1,4-lactone HMDB02541 C01115 05313-100MG 
D-Ribulose 1,5-bisphosphate HMDB11688 C01182 83895-10MG 
3-Methylbutanoyl-CoA HMDB01113 C02939 I9381-10MG 
cis-Homoaconitate  C04002 40487-10MG 
1-(5'-Phosphoribosyl)-5-amino-4-
imidazolecarboxamide (AICAR) HMDB01517 C04677 A9978-25MG 
Succinyl-CoA HMDB01022 C00091 S1129-5MG 
Glycerone phosphate HMDB01473 C00111 37442-100MG-F 
Proline betaine HMDB04827 C10172 sc-296420(Santa Cruz) 
Suberic acid HMDB00893 C08278 S5200-5G 
Oleic acid HMDB00207 C00712 O1008-1G 
Tyramine HMDB00306 C00483 T90344-5G 
Niacinamide HMDB01406 C00153 N5535-100G 
Arachidonic acid HMDB01043 C00219 A3555-10MG 
Caprylic acid HMDB00482 C06423 PHR1202-1G 
Linoleic acid HMDB00673 C01595 L1376-1G 
L-Tyrosine HMDB00158 C00082 T8566-25G 
Butyric acid HMDB00039 C00246 B103500-100ML 
cis-4,7,10,13,16,19-
Docosahexaenoic acid HMDB02183 C06429 D2534-25MG 
L-Isoleucine HMDB00172 C00407 I2752-5G 
Sebacic acid HMDB00792 C08277 283258-5G 
4-Vinylphenol HMDB04072 C05627 
sc-267756; (Santa 
Cruz), 10% solution 
in propylene glycol 
Oleamide HMDB02117 C19670 O2136-100MG 
Propionic acid HMDB00237 C00163 P1386-500ML 
Stigmasterol HMDB00937 C05442 S2424-1G 
Shikimic acid HMDB03070 C00493 S5375-1G 
N-Acetylputrescine HMDB02064 C02714 A8784-25MG 
Hexanoic acid HMDB00535 C01585 153745-2.5G 
Pyridoxamine dihydrochloride HMDB01431 C00534 P9380-1G 
N-a-Acetyl-L-arginine HMDB04620  S451029-250MG 
L-Carnitine  HMDB00062 C00318 C0158-1G 
Azelaic acid (98%) HMDB00784 C08261 246379-25G 
Dodecanedioic acid HMDB00623 C02678 D1009-100G 
Nicotinic acid HMDB01488 C00253 N4126-5G 
1,2,4-Trimethylbenzene HMDB13733 C14533 T73601-25ML 
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Isovaleric acid HMDB00718 C08262 129542-100ML 
Taurine HMDB00251 C00245 T0625-10G 
Phenylacetic acid HMDB00209 C07086 P16621-5G 
Putrescine HMDB01414 C00134 51799-100MG 
L-(+)-Lactic acid HMDB00190 C00186 L1750-10G 
Piperidine HMDB34301 C01746 76046-100MG/411027 
gamma-butyrobetaine/(3-
Carboxypropyl)trimethylammonium 
chloride 
HMDB01161 C01181 403245-1G 
D-Glyceric acid  HMDB00139 C00258 61786-10MG 
Cyclohexylamine HMDB31404 C00571 G6503-1G 
4-Guanidinobutyric acid HMDB03464 C01035 G6503-1G 
1-Oleoyl-sn-glycero-3-
phosphocholine(synthetic, ≥99%) HMDB02815 C04230 L1881-5MG 
Cadaverine HMDB02322 C01672 33211-10ML-F 
L-(−)-Fucose HMDB00174 C01019 F2252-10MG 
2-Palmitoylglycerol HMDB11533  75614-25MG 
Cholesteryl oleate HMDB00918 C14641 C9253-100MG 
Histamine HMDB00870 C00388 H7125-1G 
D-Pantothenic acid  HMDB00210 C00864 P5155-100G 
dGDP HMDB00960 C00361 D9250-25MG 
Tetradecanoyl-CoA HMDB01521 C02593 M4414-5MG 
NAD HMDB00902 C00003 N7004-250MG 
ADP HMDB01341 C00008 A2754-100MG 
FAD HMDB01248 C00016 F6625-10MG 
S-Adenosyl-L-methionine HMDB01185 C00019 A7007-25MG 
Acetyl-CoA HMDB01206 C00024 A2056-10MG 
GDP HMDB01201 C00035 G7127-25MG 
FMN HMDB01520 C00061 F2253-25MG 
GMP HMDB01397 C00144 G8377-500MG 
D-Erythrose 4-phosphate HMDB01321 C00279 E0377-10MG 
dGTP HMDB01440 C00286 D4010-10MG 
Acetoacetyl-CoA HMDB01484 C00332 A1625-10MG 
dUMP HMDB01409 C00365 D3876-100MG 
5-Aminolevulinate HMDB01149 C00430 A3785-500MG 
Homogentisate HMDB00130 C00544 H0751-100MG 
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Table S2-2. Gut OTUs containing enzymes of the D-sorbitol pathway 
OTU_IDs Consensus Lineage 
156580 k__Bacteria; p__Proteobacteria; c__Betaproteobacteria; 
o__Burkholderiales; f__Burkholderiaceae; g__Burkholderia; s__ 
4322414 k__Bacteria; p__Proteobacteria; c__Betaproteobacteria; 
o__Burkholderiales; f__Burkholderiaceae; g__Burkholderia; s__ 
49998 k__Bacteria; p__Proteobacteria; c__Betaproteobacteria; 
o__Burkholderiales; f__Burkholderiaceae; g__Burkholderia; s__ 
4311006 k__Bacteria; p__Proteobacteria; c__Betaproteobacteria; 
o__Burkholderiales; f__Burkholderiaceae; g__Burkholderia; s__ 
135993 k__Bacteria; p__Proteobacteria; c__Betaproteobacteria; 
o__Burkholderiales; f__Burkholderiaceae; g__Burkholderia; s__ 
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Table S2-3. Gut OTUs containing enzymes of the 2,5-diketo-D-gluconic acid pathway 
OTU_IDs Consensus Lineage 
4368451 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; o__Rhizobiales; 
f__Phyllobacteriaceae; g__; s__ 
221365 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
4369186 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
4343884 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
648004 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
772368 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
88754 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
2228274 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
1044767 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
639311 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
163322 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__; s__ 
929312 k__Bacteria; p__Proteobacteria; c__Alphaproteobacteria; 
o__Rhodospirillales; f__Acetobacteraceae; g__Roseomonas; s__mucosa 
236142 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
1119540 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
510870 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
819636 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
4456892 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
213522 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
540402 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
219248 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
3944484 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
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819387 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
1110763 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
238820 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
4432891 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__; s__ 
578058 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
239362 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
9939 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
138826 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
806143 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
813564 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
4430681 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
4318990 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
656889 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
4067355 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
835346 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
9826 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
9912 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
1022184 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
1134377 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
4417158 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
688934 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
167120 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
4250206 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
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585701 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
9918 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__ 
817254 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__dispersa 
539107 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__dispersa 
808540 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__dispersa 
169538 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__dispersa 
825033 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__dispersa 
372473 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Erwinia; s__soli 
3159130 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Serratia; s__ 
1726426 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Serratia; s__ 
4454068 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Serratia; s__ 
540793 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Serratia; s__ 
4360511 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Serratia; s__ 
759061 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Enterobacteriales; f__Enterobacteriaceae; g__Yersinia; s__ 
244248 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__; s__ 
4382169 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Azorhizophilus; s__ 
358042 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
133961 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
139321 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
813216 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
279948 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
171527 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
350105 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
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242070 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
104313 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
3290367 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
141206 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
218267 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
271238 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
553648 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
617271 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4435983 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
144452 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
219457 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
99682 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4475523 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4320653 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
828623 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
217410 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
513808 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
28841 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
269901 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
1119175 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4353093 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
780261 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
287032 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
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256834 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
170405 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
1118259 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4451011 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4408227 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4372132 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
170417 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
3964538 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
109263 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
227761 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
144048 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
279231 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4404312 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
544313 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
3913171 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
4389037 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
60329 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
728119 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__ 
61102 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__citronellolis 
295031 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__fragi 
327694 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; s__fragi 
247615 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__nitroreducens 
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4339214 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__nitroreducens 
226424 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__nitroreducens 
138840 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__umsongensis 
2589305 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__veronii 
276867 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__veronii 
556184 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__veronii 
4432796 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__viridiflava 
265715 k__Bacteria; p__Proteobacteria; c__Gammaproteobacteria; 
o__Pseudomonadales; f__Pseudomonadaceae; g__Pseudomonas; 
s__viridiflava 
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Figure S2-1 
 
Figure S2-1. T cell subsets in the CD4+ T population before culture. (a) Pre- and post-isolated 
CD4+ T cells were stained with cell surface markers, and assessed for % naïve/memory population 
by flow cytometry. (b) Isolated CD4+ T cells stained with cell surface surrogate markers for T cell 
subsets, and assessed for % T cell subsets by flow cytometry. 
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Figure S2-2 
 
 
Figure S2-2. Levels of human Th17 induction among study donors. (a, b) We cultured isolated 
CD4+ T cells for 14 days with Th17 polarizing cytokines, and thereafter assessed cells for 
intracellular IL-17A expression by flow cytometry and supernatant IL-17A levels by multiplex 
Luminex assay. Each bar represents data from one donor. Mean ± SEM calculated from 3 technical 
replicates. (c) XY-plot shows the correlation between intracellular and secreted IL-17A. Each dot 
represents one donor. Gray dots indicate donor samples that did not meet assay quality control cut-
off.  
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Figure S2-3  
 
Figure S2-3. Principal variance component analysis (PVCA) of contributors to total 
variability. Secreted cytokine data from four donors with three technical replicates were analyzed 
in two independent batches. Metabolites for this analysis included GDP-mannose, ascorbate, and 
L-homocysteine. The variance attributed to technical replication was <1%.  
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Figure S2-4 
 
Figure S2-4. Bioactivity of metabolites with previously reported effects on CD4+ T cells. 
Secreted cytokines levels of CD4+ T cells cultured under polarizing Th17 conditions with the 
indicated metabolites. (a) Butyric acid, (b) arachidonic acid, and (c) L-glutamate. We show data 
from two biological replicates (black and gray). Mean ± SEM calculated from three technical 
replicates.  
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Figure S2-5 
 
Figure S2-5. Metabolites with pan-effects on cytokine production. Secreted cytokines from 
CD4+ T cells cultured under polarizing Th17 conditions with the indicated metabolites. We show 
data from independent biological replicates for each metabolite (black, dark-gray, light-gray, and 
white). CoA: Coenzyme A; HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A. (a) 
Metabolites with apparent pan-inhibition. (b) Metabolites with apparent pan-enhancement. N.A., 
conditions causing cell death and hence excluded. Mean ± SEM calculated from 3 technical 
replicates.  
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Figure S2-6 
 
Figure S2-6. Metabolites with selective effects on cytokine production. Secreted cytokines 
from CD4+ T cells cultured under polarizing Th17 conditions with the indicated metabolites. (a) 
IPP: isopentenyl diphosphate. (b) Pyridoxine phosphate. N.A.: conditions that caused cell death 
and excluded. Mean ± SEM calculated from 3 technical replicates.  
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CHAPTER 3 
Association of Systemic Sclerosis with a Unique Colonic Microbial Consortium 
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Abstract 
Objective. To compare colonic microbial composition in systemic sclerosis (SSc) patients and 
healthy controls and to determine whether certain microbial genera are associated with 
gastrointestinal (GI) tract symptoms in patients with SSc.  
Methods. Healthy controls were age and sex matched (1:1) with adult SSc patients. Cecum and 
sigmoid mucosal lavage samples were obtained during colonoscopy. The microbiota in these 
samples were determined by Illumina HiSeq 2000 16S sequencing, and operational taxonomic 
units were selected. Linear discriminant analysis effect size was used to identify the genera that 
showed differential expression in SSc patients versus controls. Differential expression analysis for 
sequence count data was used to identify specific genera associated with GI tract symptoms.  
Results. Among 17 patients with SSc (88% female; median age 52.1 years), the mean 6 SD total 
GI Tract 2.0 score was 0.760.6. Principal coordinate analysis illustrated significant differences in 
microbial communities in the cecum and sigmoid regions in SSc patients versus healthy controls 
(both P=0.001). Similar to the findings in inflammatory disease states, SSc patients had decreased 
levels of commensal bacteria, such as Faecalibacterium and Clostridium, and increased levels of 
pathobiont bacteria, such as Fusobacterium and g-Proteobacteria, compared with healthy controls. 
Bifidobacterium and Lactobacillus, which are typically reduced under conditions of inflammation, 
were also increased in abundance in patients with SSc. In SSc patients with moderate/severe GI 
tract symptoms, the abundance of Bacteroides fragilis was decreased, and that of Fusobacterium 
was increased, compared with patients who had no or mild symptoms.  
Conclusion. This study demonstrates a distinct colonic microbial signature in SSc patients 
compared with healthy controls. This unique ecologic change may perpetuate immunologic 
aberrations and contribute to clinical manifestations of SSc.  
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Introduction 
Gastrointestinal (GI) tract dysfunction is a leading cause of morbidity and mortality in 
patients with systemic sclerosis (SSc)90,91. Symptoms of lower GI tract involvement, such as 
constipation, abdominal pain, diarrhea, faecal incontinence, and weight loss92, are among the most 
disruptive physical problems for SSc patients and compromise patient emotional well-being and 
quality of life93,94.  
The etiology of SSc-related lower GI tract dysfunction is largely unknown, and there are 
no effective treatment options91. The findings of some studies of upper GI tract dysfunction in 
patients with SSc have suggested that changes in the microvasculature, autonomic nervous system, 
and immune system may contribute to smooth muscle atrophy and gut wall fibrosis95-97. However, 
other evidence demonstrates that bacterial overgrowth may lead to malabsorption in these 
patients98. Marie et al 92 reported that in a study of 51 consecutively seen SSc patients, nearly half 
had positive results of an H2/CH4 breath test, and those with positive breath test results had more 
severe GI tract symptoms. Moreover, studies suggest that antibiotic therapy reduces lower GI tract 
symptoms92,99. Thus, alterations in microbial composition may potentially be a pathogenic factor 
in GI tract dysfunction in SSc.  
While no reported studies have examined whether imbalances in colonic microbial 
composition are a feature of SSc, numerous studies have demonstrated that altered microbiota can 
induce or intensify inflammation in other autoimmune diseases, such as inflammatory bowel 
disease (IBD)100. There is substantial evidence suggesting that the abundance of beneficial human 
commensal genera known to produce key energy metabolites and antiinflammatory molecules for 
mucosal health (e.g., Bacteroides, Bifidobacterium, Clostridium types IV and XIV) is decreased, 
with a concurrent increase in potential pathobiont genera (e.g., sulfate- reducing d-
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Proteobacterium, invasive g-Proteobacterium, Fusobacterium, and Actinobacteria), in patients 
with IBD101. Moreover, metaproteome analyses at the mucosal–luminal interface in patients with 
IBD have shown that specific bacterial phylotypes were associated with increases in local host 
inflammatory products102,103.  
The present study was undertaken to investigate the hypothesis that the SSc disease state 
is associated with altered colonic microbial composition at the human mucosal–luminal interface. 
We also aimed to examine the relationship between microbial composition and self-reported 
symptoms of GI tract dysfunction in SSc patients, as an initial test of the hypothesis that certain 
microbial genera contribute to the GI tract phenotype in SSc. If the hypothesis is confirmed, such 
genera could provide specific targets for intervention to avert or treat this important clinical 
dimension of SSc.  
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Materials and Methods  
Study Participants 
Patient participants were consecutively enrolled from the outpatient rheumatology clinic at 
the University of California, Los Angeles (UCLA). Eligible participants included adult (age ³18 
years) patients with SSc. Exclusion criteria included comorbid IBD, contraindication to 
undergoing a colonoscopy, and inability to have antibiotic and probiotic treatment withheld for at 
least 3 weeks prior to colonoscopy. Patients were allowed to continue taking proton-pump 
inhibitors because these agents exert minimal-to-negligible effects on colonic microbiota104.  
Healthy control colonic lavage specimens were obtained from the UCLA Pathology 
Microbiome Repository, which includes specimens from 150 healthy adult subjects. Age- and sex-
matched healthy controls were selected from this cohort by block randomization and matched with 
SSc patients at a 1:1 ratio.  
The UCLA institutional review board (IRB) approved the study protocol (IRB #13-
0011089), and written informed consent was obtained from each participant.  
Specimen procurement and pre-processing 
Participants underwent colonoscopy performed by a certified gastroenterologist (BER, JLC, 
or TG). We opted to collect mucosal instead of faecal samples, given the distinct and predictable 
compositional differences between colonic microbiota and stool microbiota demonstrated in prior 
studies105,106. In addition, by collecting lavage specimens we could ensure optimal preservation of 
the samples prior to preprocessing. Stool sample collection would have required patients to 
transport samples from home, and if sample thawing occurred, the integrity of the DNA and RNA 
would be compromised. We also planned to collect colonic biopsy samples if there was a clinical 
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indication for biopsy (ulceration, polyp, etc.). Complete details of specimen procurement and 
preprocessing are available upon request from the corresponding author. 
Gene sequencing for 16S ribosomal RNA (rRNA) and microbial composition analysis.  
The microbiota from the samples were profiled by multiplex sequencing for bacterial 
rRNA genes, using an Illumina HiSeq 2000. The exact details of this approach have been outlined 
in an earlier report by our group103 and are available upon request from the corresponding author.  
Assessment of GI tract symptoms.  
Demographic and disease-related characteristics were recorded, and participants 
completed the GI Tract 2.0 instrument (GIT 2.0) on the morning of their colonoscopy. The GIT 
has been shown to be a valid measure of GI tract symptom severity in SSc patients107. The 
questionnaire consists of 7 scales (reflux, distension/bloating, diarrhea, faecal soilage, constipation, 
emotional well-being, and social functioning). The GIT 2.0 can furthermore discriminate between 
self-rated severity of GI tract involvement (none/very mild, mild, moderate, or severe/very severe), 
and results on this instrument correlate with objective measures of GI tract dysfunction, at least in 
the upper GI tract108. Participants also completed the disability index of the Scleroderma Health 
Assessment Questionnaire, a valid measure of self-reported function that is commonly used in SSc 
studies109.  
Bioinformatics and statistical analyses.  
Operational taxonomic units (OTUs) were selected from the Greengenes database, and 
microbial OTUs were rarefied down to 15,000 reads per sample using Macqiime. To compare the 
microbial communities in SSc versus control samples, alpha diversity and beta diversity were 
analyzed. Alpha diversity, which represents the complexity of composition within members of a 
group, was calculated using the metrics of phylogenetic diversity, Chao1, observed species, and 
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Shannon index. Statistical comparison of alpha diversity between the 2 groups was performed 
using Student’s 2-sided t-test at a depth of 15,000. Beta diversity, which represents the between-
subject similarity of microbial composition and enables identification of differences between 
samples within a group, was computed in Macqiime, utilizing both unweighted and weighted 
UniFrac distances to estimate sample distributions. Analysis of variance using distance matrices 
(Adonis) significance analysis was performed for each pairwise comparison of sample groups, 
using the Adonis function from the R package. Principal coordinate analysis (PCoA) was 
performed to visualize the resulting UniFrac distance matrix.  
Analyses were performed using R version 3.1.2. Means and standard deviations were used 
to describe continuous parametric data, and medians and interquartile ranges were used to describe 
continuous nonparametric data. All tests were 2-sided with an alpha level of 0.05. We used the 
false discovery rate (FDR) of Benjamini and Hochberg110, and significant association was defined 
at the FDR q value threshold of  <0.1. Cecum and sigmoid findings were treated as separate data 
sets because prior studies have demonstrated biogeographic differences in mucosal samples from 
these 2 regions111.   
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Results 
Participant characteristics.  
Seventeen patients with SSc (15 women [88%] and 2 men [12%]) underwent colonoscopy 
and completed the questionnaire. Sigmoid and cecum lavage samples were obtained from all 
patients except 1, from whom only a sigmoid lavage sample was obtained. None of the patients 
had a clinical indication for colonic biopsy; therefore, these specimens were not collected. Clinical 
characteristics are shown in Table 3-1. The median age of the patients was 52.1 years, and the 
median disease duration was 6.6 years. The mean total score on the GIT 2.0 was 0.7, indicating 
moderate symptom severity. Scores on individual domains of the GIT 2.0 indicated moderate 
severity (distention/bloating, social functioning, emotional well-being, and constipation) or mild 
severity (faecal soilage and diarrhea). Six patients (35%) had taken antibiotics in the 3 months 
preceding the colonoscopy; the mean time between cessation of antibiotic treatment and 
colonoscopy was 6.5 weeks (range 4-12). None of the patients used tobacco products, and only 5 
had consumed alcohol regularly within the previous month (mean ± SD 2.8 ± 1.5 servings of 
alcohol per week).  
Altered colonic microbial diversity in patients with SSc.  
After OTU selection, a total of 5,442 and 5,593 species-level OTUs were generated from 
the cecum and sigmoid data sets, respectively. The SSc and control participants exhibited similar 
alpha diversity (i.e., the complexity of microbial composition) based on the following metrics 
(cecum P value and sigmoid P value, respectively): phylogenetic diversity (P=0.2; P=0.1), 
observed species (P=0.4; P=0.2); and Shannon index (P=0.7; P=0.6). Compared with controls, 
SSc patients exhibited a trend toward increased alpha diversity based on the Chao 1 diversity 
metric, which estimates OTU richness in microbial communities112 (P=0.07 and P=0.09 for the 
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cecum and sigmoid regions, respectively; data available upon request from the corresponding 
author); this suggests that the SSc disease state is associated with a potential increase in bacterial 
diversity. 
Beta diversity was then computed to determine whether microbial composition differed 
between SSc patients and control subjects. The PCoA visualization of unweighted UniFrac 
distances and Adonis analysis of this comparison is shown in Figure 3-1. In both the cecum and 
the sigmoid regions, the microbial composition among SSc patients was significantly different 
from that in healthy controls (P=0.001 for both regions). Significant differences between SSc 
patients and healthy subjects were also observed by weighted UniFrac distances (P=0.03 for 
Adonis analysis of both regions).  
Differential abundance of numerous colonic microbial genera in SSc patients.  
To begin to define the compositional differences between SSc patients and healthy controls 
predicted by the beta diversity analysis, the relative abundances of microbial composition at 
different taxonomic levels were computed. The 3 predominant phyla in SSc samples were 
Bacteroidetes (cecum 47.2%; sigmoid 46.7%), Firmicutes (cecum 23.3%; sigmoid 25.2%), and 
Proteobacteria (cecum 23.1%; sigmoid 20.5%). Similar to findings in an earlier study of the 
microbiome in IBD15, the relative abundances of Verrucomicrobia, Fusobacterium, and 
Actinobacteria were significantly increased in cecum samples from SSc patients compared with 
controls (q=0.03, q=0.02, and q=0.003, respectively). Additional data from this analysis are 
available upon request from the corresponding author.  
The taxonomic differences between SSc patients and healthy controls at the genus level 
were assessed by linear discriminant analysis (LDA) effect size multivariate analysis (to correct 
for species abundance). The microbial enrichments and depletions in the cecum and the sigmoid 
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that reached significance after correction for multiple testing (q<0.1) are shown in Figure 3-2 and 
2-3. In the cecum, commensal genera such as Faecalibacterium, Clostridium, and Rikenella were 
depleted in SSc patients, whereas Fusobacterium, Prevotella, and the uncommon g-Proteobacteria, 
Erwinia, and Trabsulsiella were enriched in SSc patients. Similarly, in the sigmoid, 
Faecalibacterium and Rikenella were depleted in SSc patients, whereas numerous sigmoid genera, 
such as Fusobacterium and Prevotella, were enriched. Surprisingly, 2 commensal bacterial genera 
(Lactobacillus and Bifidobacterium) were found in greater abundance in SSc patients compared 
with controls in both the sigmoid and cecum regions (Figure 3-2 and 3-3). These 2 species are 
typically reduced in abundance in chronic inflammatory states, such as IBD113.  
Association of specific microbial genera and species with GI tract symptoms in patients 
with SSc.  
Multivariate analysis with differential expression analysis for sequence count data was 
used to identify microbial taxa associated with GI tract symptoms as assessed based on the GIT 
2.0 total score and individual domains (constipation, diarrhea, or distention/bloating). For the total 
score or domains, SSc patients were dichotomized into low (none-to-mild) or high (moderate-to-
severe) disease severity groups. The fold difference in the abundance of specific organisms 
between disease severity groups was calculated (Figure 3-4), and for organisms with significant 
differences between groups, q values were tabulated (data available upon request from the 
corresponding author). The level of Bacteroides fragilis in both the cecum and the sigmoid was 
elevated in patients with mild disease (GIT 2.0 total score, diarrhea domain, and 
bloating/distension domain). Candidatus arthromitus had a similar association with mild disease, 
but only in the cecum. Conversely, genus-level members of the Fusobacterium genus and the 
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Actinobacillus genus were associated with severe disease, but more prominently in the sigmoid 
region and more heterogeneously with respect to symptom domains.  
Differences in microbial composition by SSc subtype.  
In an exploratory analysis, we compared beta diversity between SSc patients with limited 
cutaneous disease (lcSSc; n=11) and those with diffuse cutaneous disease (dcSSc; n=6). 
Differences in beta diversity were significant by Adonis in the cecum (R2= 0.13, P=0.011) but not 
in the sigmoid (R2=0.08, P=0.2), as calculated using unweighted UniFrac distances. However, 
only a small amount of the variation (13%, as reflected by the R2 value) could be explained by this 
subtype grouping for the cecum. LDA effect size multivariate analysis was used to examine the 
taxonomic differences between patients with lcSSc and dcSSc at the genus level. After correction 
for multiple testing (q<0.1), the abundance of Lactobacillus from the Firmicutes phylum was 
higher in patients with lcSSc (LDA 2.7), while that of Paludibacter from the Bacteroidetes phylum 
was lower in patients with lcSSc (LDA 2.7), compared with patients with dcSSc.  
Altered metabolic proficiencies of microbiota in SSc patients.  
To compare the functional proficiencies of the microbial communities in SSc patients and 
healthy controls, the imputed metagenomic composition in each patient was determined using 
PICRUSt (phylogenetic investigation of communities by reconstruction of unobserved states), and 
compared by calculating Bray-Curtis distance matrices and visualizing by PCoA. Differences in 
metagenomic content between SSc patients and healthy controls reached significance by Adonis 
in both the cecum region (R2=0.9, P=0.016) and the sigmoid region (R2=0.9, P=0.007).  
Among all of the imputed genes, 66 in the cecum region and 89 in the sigmoid region 
showed significant differences (q<0.1) in SSc patients compared with healthy controls. Of these 
significantly dysregulated genes, 41 in the cecum region and 47 in the sigmoid region were mapped 
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to biologic pathways through the Kyoto Encyclopedia of Genes and Genomes pathway database. 
A complete list of gene differences and their associated pathways is presented in Supplementary 
Table 3-1, available on the Arthritis & Rheumatology website at 
http://onlinelibrary.wiley.com/doi/10.1002/art. 39572/abstract. SSc patients had a significantly 
decreased abundance of genes involved in amino sugar and nucleotide sugar metabolism, such as 
N-acylneuraminate cytidylyltransferase (K00983; log LDA effect size in the cecum and sigmoid, 
respectively 2.0 [q=0.001] and 2.1 [q=0.001]) and b-hexosaminidase (K12373; log LDA effect 
size in the cecum and sigmoid, respectively 2.4 [q=0.07] and 2.5 [q=0.04]), as well as genes 
involved in sphingolipid metabolism, such as b-galactosidase (K01190; log LDA effect size in the 
cecum and sigmoid, respectively 2.7 [q=0.02] and 2.8 [q=0.007]) (Figure 3-5).  
 66 
Discussion 
The present study is, to our knowledge, the first to define colonic microbial composition 
in adult patients with SSc. We report a unique colonic microbial consortium in SSc patients, 
characterized by significant increases in Fusobacterium, Prevotella, and uncommon g-
Proteobacteria (i.e., Erwinia and Trabsulsiella) genera and significant decreases in 
Faecalibacterium and Clostridium genera, compared with age- and sex-matched healthy controls. 
Interestingly, the SSc microbial consortium was also enriched with Lactobacillus and 
Bifidobacterium, 2 commensal genera typically found in lower abundance in chronic inflammatory 
states.  
Fusobacterium species represent a group of gram-negative anaerobes that principally 
colonize the oral cavity. When present in the colon, these species are considered pathobionts given 
their invasive nature and ability to translocate into the blood and contribute to systemic processes, 
including bacteremia, organ abscesses, and possibly coronary artery disease114,115. In patients with 
Crohn’s disease, Fusobacterium species are increased compared with controls116, and human 
isolates of Fusobacterium varium induce colonic mucosal erosions in mice117. Moreover, 
Fusobacterium isolates recovered from IBD patients demonstrate enhanced invasive and pro-
inflammatory properties in cultured epithelial cell assays than those strains isolated from healthy 
individuals 118, further implicating these species in the pathogenesis of IBD. 
Prevotella species were also enriched in SSc patients compared with healthy controls. 
These genera are increased in patients with Crohn’s disease119, as well as in patients with new-
onset rheumatoid arthritis6. A recent study demonstrated that inflammation was increased in mice 
with dextran sulfate sodium-induced colitis that were colonized with Prevotella copri, in 
particular6.  
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The observation that Fusobacterium and Prevotella are increased in SSc patients compared 
with controls suggests that these species may play a role in the development of the SSc GI tract 
phenotype. Additional studies are needed to elucidate their pathogenic potential in SSc. Given the 
established link between diet and Prevotella120, there may be a future role for dietary modification 
in averting GI tract symptoms in SSc.  
The genera that were depleted in SSc, most notably Faecalibacterium and Clostridium 
species, are commensal organisms, which may protect against mucosal inflammation and 
colonization of pathogenic species121. For example, Faecalibacterium prausnitzii is decreased in 
IBD122. Low levels of mucosa-associated F. prausnitzii are associated with a higher risk of recur- 
rent Crohn’s disease after surgery123, whereas recovery of F. prausnitzii after relapse is associated 
with maintenance of clinical remission in ulcerative colitis124. Moreover, Clostridium species have 
been found to induce the expansion of regulatory T cells, thereby reducing intestinal 
inflammation125.  
A surprising observation in this study was the significant increase in Bifidobacterium and 
Lactobacillus among SSc patients compared with healthy controls. Lactobacillus was also more 
abundant in patients with lcSSc compared with those with dcSSc, although the latter finding should 
be interpreted with caution given the exploratory nature of this subgroup analysis. While 
Bifidobacterium and Lactobacillus are typically depleted in chronic inflammatory states, a recent 
study of patients with enthesitis-related arthritis also demonstrated an increase in Bifidobacterium 
in stool samples from children with this disorder, compared with controls126.  
Taken together, these findings suggest that our traditional views of “protective” commensal 
species need to be considered in the context of the underlying disease state. Given the myriad of 
ways in which the phenotypic expression of SSc differs from that of other autoimmune diseases, 
 68 
it is not surprising that the microbial consortium in SSc is unique. Moreover, our results may 
indicate that therapeutic efforts to increase commensal organisms in SSc (i.e., currently available 
commercial probiotics, which commonly include Lacto- bacillus or Bifidobacter species) should 
be targeted only toward select organisms.  
In addition to identifying distinct features of the SSc colonic microbial consortium, we 
have elucidated relationships between specific microbial genera/species and the SSc GI tract 
phenotype. Increased abundance of Fusobacterium and decreased abundance of B. fragilis and C. 
arthromitus were associated with increased GI tract symptom severity, as measured by the GIT 
2.0 total score as well as many of the individual GIT 2.0 domains reflecting lower GI tract 
dysfunction. If B. fragilis and C. arthromitus are validated in future studies to attenuate mucosal 
inflammation in SSc, therapy directed at increasing the growth or activity of these species to 
ameliorate GI tract symptoms in SSc would merit testing.  
Furthermore, the finding of differences in predicted metagenomic pathways between SSc 
patients and healthy controls implies that the compositional shifts observed in this study likely 
correspond to altered functional capacity of the SSc-associated microbiome relative to a healthy 
microbiome. These pathways may mediate the relationship between microbiota composition and 
GI tract symptoms and warrant further investigation.  
The nature and findings of the present study should be placed in the context of certain 
limitations. First, the study was cross-sectional, and it is unclear whether the observed relationships 
between specific genera and GI tract symptoms persist with time. To address this question, a 12-
month longitudinal study of this cohort is currently under way. Second, there may be a small batch 
effect as the sequencing analysis was per- formed for the control samples prior to the SSc samples. 
Given that the sequencing protocol was identical for both groups and that the observed differences 
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between SSc patients and controls were highly significant, however, a possible batch effect is 
unlikely to fully explain the differences. Third, the sample size was small, and the results would 
need to be confirmed in a validation cohort. Despite the small sample size, however, we observed 
several significant associations, suggesting that it is unlikely the present findings are due to chance 
alone. Fourth, because of the small sample size and concerns regarding multiple hypothesis testing 
(Type I error), we were unable to perform meaningful subgroup analyses to compare the 
microbiota in patients with different disease characteristics (e.g., negative versus positive for Scl-
70 antibody). Fifth, colonic motility was not assessed in this study since there is presently no valid 
measure of colonic motility in SSc. However, for future studies investigators may consider using 
potential surrogate measures of motility, such as anal endosonography and/or manometry. This 
may help elucidate the effects (if any) of intestinal dysmotility on microbial composition in SSc, 
or vice versa. Future studies assessing dietary intake patterns to ascertain whether certain dietary 
features (e.g., gluten- free, dairy-free, high animal protein, etc.) affect colonic microbiota may also 
provide useful insights.  
An additional unanswered question of our study is whether the observed shifts in the 
colonic microbial consortium in SSc are present prior to the development of GI tract symptoms. A 
study of patients with very early SSc, such as the Very Early Diagnosis of SSc cohort127, may help 
to discern whether these shifts contribute to SSc GI tract pathogenesis.  
The present study also has several strengths. First, we obtained specimens during 
endoscopy at 2 colonic regions, which, in contrast to stool collection, facilitates in-depth 
investigation of the microbiota at the mucosal–luminal surface. Second, we ensured that all 
antibiotic and probiotic medications were withheld for at least 3 weeks prior to colonoscopy, by 
verifying medication lists 3 times in the month preceding the colonoscopy. Third, we performed 
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sophisticated statistical analyses to correct for multiple hypothesis testing, using a relatively 
conservative FDR q value. Fourth, the multivariate method used for comparing metagenomic data 
(LDA effect size) allowed us to control for relative species abundance and also provided an 
estimate of the magnitude of the observed difference. Finally, by including a clinical outcome 
measure, we have endeavored to discern how changes in the microbiome in SSc contribute to GI 
tract symptoms.  
In conclusion, utilizing an innovative experimental strategy to identify bacterial genera 
associated with SSc we have identified, for the first time, a colonic microbial consortium unique 
to the SSc disease state. Using an integrative bioinformatics approach, we also demonstrated 
relationships between specific genera and clinical manifestations of SSc, which merit further 
investigation. Interestingly, many of the increased and decreased organisms identified in SSc are 
similar to those found in Crohn’s disease, which, like SSc, has both inflammatory and fibrosing 
pathologic features. Further studies are needed to validate and expand on the present findings.  
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Tables and Figures 
Table 3-1. Study patient characteristics* 
 
SSc participants 
(N=17) 
Healthy controls 
(N=17) 
Age, median (IQR) years 52.1 (46.6-63.0) 55.0 (51.0-62.0) 
Female 15 (88.2) 15 (88.2) 
Race   
   White 9 (52.9) 15 (88.2) 
   Asian 2 (11.8) 0 
   More than one race 4 (23.5) 0 
   Other 2 (11.8) 1 (5.9) 
Hispanic Ethnicity 6 (35.3) 1 (5.9) 
Diffuse cutaneous disease 6 (35.3) NA 
SSc duration, median (IQR) years 6.6 (2.5-16.4) NA 
Antinuclear antibody positive 15 (93.8) NA 
Anti-Scl-70 positive 3 (27.3) NA 
Anticentromere antibody positive 5 (45.5) NA 
HRCT-defined ILD 12 (70.6) NA 
Current prednisone use† 3 (17.6) NA 
Current use of other immunosuppressive agent‡ 3 (17.6) NA 
Current use of probiotic oral supplement§  3 (17.6) NA 
Current use of proton-pump inhibitor  10 (58.8) NA 
Scleroderma HAQ DI (023), mean ± SD  1.1±0.6 NA 
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GIT 2.0, mean ± SD    
    Total score 0.7±0.6¶ NA 
    Distension/bloating score 1.5±0.9¶ NA 
    Diarrhea score 0.4±0.6# NA 
    Faecal soilage score 0.5±0.9# NA 
    Constipation score 0.7±0.7¶ NA 
    Emotional well-being score 0.5±0.7¶ NA 
    Social functioning score 0.5±0.5¶ NA 
 
* Information on antibody status was missing in some cases (data on antinuclear antibody 
positivity, anti-Scl-70 positivity, and anticentromere antibody positivity are from 16 patients, 11 
patients, and 11 patients, respectively). Except where indicated otherwise, values are the number 
(%). SSc = systemic sclerosis; IQR = interquartile range; NA = not applicable; HRCT = high-
resolution computed tomography; ILD = interstitial lung disease; HAQ DI = Health Assessment 
Questionnaire disability index; GIT 2.0 = Gastrointestinal Tract 2.0 questionnaire.  
† Dosages of ≤10 mg daily in all cases. 
‡ Mycophenolate mofetil in 1 patient; azathioprine in 2 patients.   
§ Culturelle (Lactobacillus rhamnosus GG) in 1 patient, Align (Bifidobacterium infantis) in 1 
patient, and Florify in 1 patient. Probiotics were not consumed within 3 weeks of the colonoscopy.  
¶ Score indicates moderate symptom severity107 
# Score indicates mild symptom severity107 
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Figure 3-1 
 
 
Figure 3-1. Significant differences in the beta diversity of samples from the cecum and sigmoid 
regions of systemic sclerosis patients (open circles) and healthy controls (solid circles), as 
demonstrated in principal coordinate (PC) analysis plots of the unweighted UniFrac distance. For 
both the cecum region and the sigmoid region, R2=0.9, P=0.001 (by analysis of variance using 
distance matrices) between patients and controls.  
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Figure 3-2 
 
Figure 3-2. Genus-level taxa in the cecum that were associated with systemic sclerosis (SSc) (as 
determined by comparing with healthy subjects). Linear discriminant analysis (LDA) effect size 
multivariate analysis was used to identify significant associations (q<0.1), and LDA was used to 
calculate the effect size for these associations. Negative (red) and positive (green) effect sizes 
denote genera that were decreased and increased, respectively, in patients with SSc. Color figure 
can be viewed in the online issue, which is available at http://onli- 
nelibrary.wiley.com/journal/doi/10.1002/art.39572/abstract.  
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Figure 3-3 
 
Figure 3-3. Genus-level taxa in the sigmoid that were associated with systemic sclerosis (SSc) (as 
determined by comparing with healthy subjects). Linear discriminant analysis (LDA) effect size 
multivariate analysis was used to identify significant associations (q<0.1), and LDA was used to 
calculate the effect size for these associations. Negative (red) and positive (green) effect sizes 
denote genera that were decreased and increased, respectively, in patients with SSc. Color figure 
can be viewed in the online issue, which is available at 
http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39572/abstract.  
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Figure 3-4 
 
Figure 3-4. Bacterial taxa associated with the Gastrointestinal Tract 2.0 (GIT 2.0) total score and 
individual domains. Patients were dichotomized into low (none-to-mild) or high (moderate-to-
severe) disease severity groups for the GIT 2.0 total score and the individual domains 
bloating/distension, diarrhea, and constipation. Multivariate analysis with differential expression 
analysis for sequence count data was used to identify microbial taxa that were significantly 
associated with low versus high disease severity and to calculate the fold change between groups. 
Positive and negative change scores denote organisms whose abundance was increased and 
decreased, respectively, in low disease severity groups. B. fragilis =Bacteroides fragilis; C. 
arthromitus =Candidatus arthromitus; g=genus-level taxa.  
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Figure 3-5 
 
Figure 3-5. Significant differences in metagenomic content in the sigmoid and cecum regions 
between systemic sclerosis (SSc) patients and healthy controls. Linear discriminant analysis 
(LDA) effect size multivariate analysis was used to identify significant associations (q<0.1), and 
LDA was used to calculate the effect size for these associations (see Supplementary Table 3-1, 
available on the Arthritis & Rheumatology website at http:// 
onlinelibrary.wiley.com/doi/10.1002/art.39572/abstract). A positive LDA score indicates genes 
and pathways that were decreased in SSc patients compared with healthy controls. KEGG = 
Kyoto Encyclopedia of Genes and Genomes. Color figure can be viewed in the online issue, 
which is available at http://onlinelibrary.wiley.com/journal/doi/10.1002/art.39572/abstract.  
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CHAPTER 4 
Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in 
two independent cohorts 
 79 
Abstract 
Objective. To compare faecal microbial composition in patients with systemic sclerosis (SSc) 
from 2 independent cohorts with controls and to determine whether certain genera are associated 
with SSc gastrointestinal tract (GIT) symptoms.  
Design. Adult patients with SSc from the University of California, Los Angeles (UCLA) and Oslo 
University Hospital (OUH) and healthy controls participated in this study (1:1:1). All participants 
provided stool specimens for 16S rRNA sequencing. Linear discriminant analysis effect size 
demonstrated genera with differential expression in SSc. Differential expression analysis for 
sequence count data identified specific genera associated with GIT symptoms as assessed by the 
GIT 2.0 questionnaire.  
Results. The UCLA-SSc and OUH-SSc cohorts were similar in age (52.1 and 60.5 years, 
respectively), disease duration (median (IQR): 6.6 (2.5–16.4) and 7.0 (1.0–19.2) years, 
respectively), gender distribution (88% and 71%, respectively), and GIT symptoms (mean (SD) 
total GIT 2.0 scores of 0.7 (0.6) and 0.6 (0.5), respectively). Principal coordinate analysis 
illustrated significant microbial community differences between SSc and controls (UCLA: 
p=0.001; OUH: p=0.002). Patients with SSc had significantly lower levels of commensal genera 
deemed to protect against inflammation, such as Bacteroides (UCLA and OUH), Faecalibacterium 
(UCLA), Clostridium (OUH); and significantly higher levels of pathobiont genera, such as 
Fusobacterium (UCLA), compared with controls. Increased abundance of Clostridium was 
associated with less severe GIT symptoms in both cohorts.  
Conclusions. The present analysis detected specific aberrations in the lower GIT microbiota of 
patients with SSc from 2 geographically and ethnically distinct cohorts. These findings suggest 
that GIT dysbiosis may be a pathological feature of the SSc disease state.  
 80 
Summary box  
What is already known about this subject?  
-   Gastrointestinal tract dysfunction affects over 90% of patients with systemic sclerosis.   
-   The pathogenesis of lower gastrointestinal tract dysfunction in systemic sclerosis is largely 
unknown.   
-   Emerging evidence suggest that gastrointestinal tract dysbiosis may be a feature of the systemic 
sclerosis disease state.   
What are the new findings?   
-   The study found specific alterations in the gastrointestinal microbiota in two independent 
systemic sclerosis cohorts.   
-   The extent of dysbiosis (i.e. alterations in the intestinal microbiota) appeared greatest in patients 
from the American SSc cohort compared with those from the Norwegian SSc cohort.   
-   Specific genera were associated with severity of gastrointestinal tract symptoms.  
How might it impact on clinical practice in the foreseeable future?   
-   Currently, few effective treatment options exist for managing lower gastrointestinal tract 
symptoms in patients with systemic sclerosis. If specific genera are found to contribute the 
gastrointestinal tract phenotype in systemic sclerosis, such genera could provide specific targets 
for intervention to avert or treat this important clinical dimension of systemic sclerosis. 
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Introduction 
The majority of patients with systemic sclerosis (SSc) experience gastrointestinal tract 
(GIT) dysfunction.90,91 Symptoms of lower GIT involvement92 adversely affect quality of life and 
social functioning.93,94 Unfortunately, no effective treatment options exist for eliminating these 
disruptive symptoms, largely because the pathogenesis of this dimension of SSc is poorly 
understood.  
GIT dysbiosis occurs in a number of chronic inflammatory conditions, including 
inflammatory bowel disease (IBD),100-103 and recent studies suggest that alterations in GIT 
microbiota may be a feature of the SSc disease state.92,128 Our prior study demonstrated that 
patients with SSc had decreased abundance of beneficial human commensal genera known to 
produce key energy metabolites and anti-inflammatory molecules for mucosal health (eg, 
Faecalibacterium; Clostridium) with a concurrent increase in potential pathobiont genera (eg, 
invasive γ-Proteobacteria; Fusobacterium), compared with controls.128 
This study also demonstrated that increased abundance of Clostridium and decreased 
abundance of Fusobacterium were independently associated with decreased GIT symptoms.128 To 
further explore whether alterations in microbial composition may serve as a pathogenic factor in 
SSc-GIT dysfunction, the present study examined the lower GIT microbiota from two independent 
SSc cohorts. Whereas our prior study examined colonic mucosal microbes via colonoscopy, the 
present study examined stool specimens from the same patients with SSc.128 Assessment of stool 
specimens may reflect other aspects of the gut microbiota (eg, metabolic features) and can be 
obtained by a less invasive approach.  
The objectives of this study, not previously explored in the SSc literature, were to: (1) 
establish whether analysis of stool specimens can distinguish the GIT microbiota of patients with 
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SSc versus healthy controls; (2) compare the GIT microbiota of patients with SSc from two geo- 
graphically independent cohorts; and (3) evaluate the hypothesis that specific microbial genera are 
associated with SSc-GIT symptom severity.  
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Materials and Methods 
Study Participants 
Patient participants were consecutively enrolled from the outpatient rheumatology clinics 
at University of California, Los Angeles (UCLA) and Oslo University Hospital (OUH). Eligible 
participants included adult (≥18years) patients with SSc, according to the 2013 American College 
of Rheumatology/European League Against Rheumatism Classification Criteria for SSc.129 
Exclusion criteria included IBD, inability to withstand from taking an antibiotic and a probiotic 
for at least 3weeks prior to the stool collection. Patients were allowed to continue taking a proton 
pump inhibitor medication because this agent exerts negligible effects on colonic microbiota104. 
Healthy controls stool specimens were obtained from the UCLA Specialized Center of 
Research in Neurovisceral Sciences and Women’s Health Repository, which consists of stool 
specimens from healthy adult participants (12 men and 9 women) who do not have GIT symptoms. 
These control participants were different than the control participants used in our prior study.128 
We attempted to match 17 of these healthy participants by age and sex with the UCLA-SSc cohort 
patients (1:1); however, the healthy control cohort had more men than women so gender matching 
was not always possible. These healthy controls specimen also served as the controls for the OUH-
SSc cohort.  
The UCLA Institutional Review Board and the Regional Committee of Health and Medical 
Research Ethics in Norway approved the study protocol and written informed consent was 
obtained from each participant.  
Specimen procurement and processing 
Participants at both sites collected stool specimens using our previously published, 
standard collection method130 and immediately froze the specimen. Frozen specimens were 
 84 
subsequently transferred on ice to the participant’s study centre and stored at −80°C. OUH 
specimens were shipped overnight on dry ice to UCLA for further processing. Please see the online 
supplementary appendix for complete details of specimen procurement and processing.  
16S rRNA gene sequencing and microbial composition analysis 
The microbiota from the stool specimens were profiled by multiplex sequencing for 
bacterial rRNA genes using an Illumina HiSeq 2500 (Illumina, San Diego, California, USA) 
sequence technique. All samples (UCLA-SSc, OUH-SSc, controls) were analyzed simultaneously 
at UCLA to avoid any batch effects. The exact details of this approach have been outlined in our 
prior publication,103,128 and are summarized in the online supplementary appendix.  
Faecal calprotectin  
Faecal calprotectin concentrations were measured in duplicate from the stool specimens of 
the UCLA-SSc and healthy control participants using a commercial kit (KTR-849, Epitope 
Diagnostics, San Diego, California, USA) according to the manufacturer’s instructions.  
Assessment of GIT symptoms 
On the day of their stool collection, the UCLA and OUH-SSc participants completed the GIT 2.0, 
a valid measure of GIT symptom severity in SSc patients107. The questionnaire consists of seven 
domains and has been translated and validated in several languages, including Norwegian. The 
GIT 2.0 can furthermore discriminate between self-rated severity (i.e. none/mild versus moderate 
versus severe/very severe disease) of GIT involvement107.   
Statistical and bioinformatics analyses 
Statistical approach 
Analyses were performed using R V.3.1.2. Mean and SDs were used to describe continuous 
parametric data; median and IQRs were used to describe continuous non-parametric data. All tests 
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were two-sided with a 0.05 α level. To compare the microbial communities of SSc versus control 
samples, α and β diversity were analysed. The α diversity represents the complexity of composition 
within members of a group, and β diversity represents the between-participant similarity of 
microbial composition and enables the identification of differences between samples within a 
group. We also examined taxo- nomic differences at specific levels (ie, phylum, genus) using linear 
discriminant analysis effect size (LefSe). We used the false discovery rate (FDR) of Benjamini 
and Hochberg110, and a significant association was defined at the FDR q-value ≤0.1. Please see the 
online supplementary appendix for further details.  
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Results 
Participant characteristics 
Seventeen UCLA-SSc cohort patients (88% women; median age 52.1 years) and 17 OUH-
SSc cohort patients (71% women; median age 60.5years) were enrolled (Table 4-1). The healthy 
control cohort (N=17) was younger than the SSc cohorts (median age 29.0 years), and had a 
predominance of women (60% women). The OUH-SSc cohort was mostly Caucasian (94%); 
whereas the UCLA-SSc and healthy control cohorts had more Hispanics (35% and 24%, 
respectively, vs 6% in the OUH-SSc cohort). The mean body mass index (BMI) was similar in the 
two SSc cohorts (∼24 for both cohorts) and slightly higher in the controls (28.1), although the 
difference in BMI between SSc participants and healthy controls was not significant.  
UCLA-SSc and OUH-SSc cohort patients had similar SSc disease durations, proportion of 
patients with diffuse cutaneous sclerosis, and autoantibody profiles (Table 4-1). However, more 
patients in the UCLA-SSc cohort (71%) had clinically significant interstitial lung disease (ILD) 
by high-resolution CT131, compared with the OUH-SSc cohort (47%).  
The UCLA-SSc and OUH-SSc cohorts also had similar GIT symptom profiles (Table 4-1). 
The mean GIT 2.0 scores indicated moderate symptom severity107 for the total score, as well as for 
the following domains: distension/bloating, emotional well-being and constipation (Table 4-1). 
The mean GIT 2.0 scores for faecal soilage and diarrhea indicated mild symptom severity107 (Table 
4-1). Six UCLA-SSc participants (35%) had taken antibiotics in the 3 months preceding stool 
collection; the mean time between cessation of antibiotics and stool collection was 6.5 weeks 
(range 4–12 weeks). None of the OUH-SSc cohort patients had taken antibiotics 3 months prior to 
stool sampling.  
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Only three of the UCLA-SSc cohort patients had ele- vated levels of faecal calprotectin, 
which was defined as >50 µg/g. None of the control participants had elevated levels of faecal 
calprotectin.  
Colonic microbial diversity in SSc  
After the operational taxonomic unit (OTU) selection process, a total of 231, 250 and 184 
species-level OTUs were generated from the UCLA-SSc, OUH-SSc and healthy control cohorts, 
respectively. The α diversity (ie, the complexity of microbial composition) was similar between 
the UCLA-SSc and control participants (Figure S4-1) and between the OUH-SSc and control 
participants (Figure S4-2). There were also no significant differences in α diversity between the 
UCLA-SSc and OUH-SSc participants (Figure S4-3).  
The β diversity was then computed to determine whether SSc and control participants 
differed in their microbial composition. The principle coordinate analysis visualization of the 
weighted Unifrac distances and analysis of variance using distance matrices (Adonis) of this 
comparison are shown in Figure 4-1. In the UCLA-SSc (R2 0.355; p=0.001) and the OUH-SSc (R2 
0.126; p=0.002) cohorts, the microbial composition among patients with SSc was significantly 
different than healthy controls. The magnitude of this difference appeared greater between the 
UCLA-SSc cohort and healthy con- trols than between the OUH-SSc cohort and healthy controls 
based on the R2 values and as illustrated in Figure 4-1. The β diversity also differed between the 
UCLA-SSc and OUH-SSc cohort patients (R2 0.145; p=0.002).  
Colonic microbial genera are differentially abundant in patients with SSc   
To begin to define the compositional differences between patients with SSc and healthy 
controls predicted by the β diversity analysis, the relative abundances of microbial composition at 
different taxonomic levels were computed (Figure 4-2). The two predominant phyla in SSc 
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samples were Bacteroidetes (UCLA: 21.3%; OUH: 45.0%; controls: 63.2%), and Firmicutes 
(UCLA: 63.5%; OUH: 42.8%; controls: 33.0%). The relative abundance of Bacteroidetes was 
significantly decreased in the UCLA-SSc cohort compared with the healthy control cohort 
(p<0.0001) and in the OUH-SSc cohort compared with the healthy control cohort (p=0.009).  
LefSe multivariate analysis demonstrated significant taxonomic differences between SSc 
and healthy controls at the genus level for the UCLA-SSc (Figure 4-3) and OUH-SSc (Figure 4-4) 
cohorts. The LefSe analysis comparing the UCLA-SSc and healthy control cohorts yielded more 
significant genus-level differences than the analysis comparing the OUH-SSc and healthy control 
cohorts.  
Commensal genera such as Faecalibacterium (UCLA), Clostridium (OUH) and 
Bacteroides (UCLA, OUH) were depleted in patients with SSc; whereas, Fusobacterium (UCLA), 
Ruminococcus (UCLA) and the uncommon γ-Proteobacteria, Erwinia (UCLA), were enriched in 
patients with SSc, compared with health controls. Consistent with our prior study128, Lactobacillus 
(considered to be a commensal genus113) was found in greater abundance in patients with SSc 
compared with controls in the UCLA and OUH cohorts (Figure 4-3 and 4-4).  
When comparing the UCLA-SSc and OUH-SSc cohorts, the LefSe analysis revealed that 
specific commensal genera, including Faecalibacterium and Bacteroides, were significantly more 
abundant in the OUH-SSc cohort patients compared with the UCLA-SSc cohort patients (fold 
change scores of 4.85 and 3.75, respectively).  
Specific microbial genera and species are associated with SSc-GIT symptoms   
Differential expression analysis for sequence count data multivariate analysis identified 
specific microbial genera associated with SSc-GIT symptom severity based on the scores for the 
total GIT 2.0 and individual domains (eg, constipation, diarrhea or distension/bloating). For the 
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total score and each domain, patients were dichotomised into low (none-to-mild) or high 
(moderate-to-severe) GIT symptom severity groups, and the fold change and q-values for 
organisms reaching significance were tabulated (Table S4-1). The frequency of distribution of 
patients in each disease severity category were fairly well balanced (N for low vs high groups): 
total score (18 vs 16); constipation (16 vs 18); distention/bloating (8 vs 26) and diarrhea (18 vs 
15).  
In both SSc cohorts, Clostridium was more abundant in patients with low GIT symptom 
severity (for the total GIT score and the bloating/distension domain) compared with patients with 
high GIT symptom severity (Figure 4-5 and see Table S4-1). Lactobacillus was more abundant in 
patients with none-to-mild constipation compared with patients with moderate-to-severe 
constipation. In contrast, Prevotella was more abundant in patients with moderate-to-severe GIT 
symptom severity (bloating/distention domain, diarrhea domain) compared with patients with 
none-to-mild GIT symptom severity.  
Specific microbial genera are associated with SSc-ILD phenotype 
To ask if gut microbiome is associated the ILD phenotype in SSc, we included 34 adult 
SSc patients from UCLA and OUH cohorts. They were grouped into two clinical phenotypes based 
on their ILD records: Yes, the patients have developed ILD; No, the patients have not yet 
developed ILD. The method of linear discriminant analysis (LDA) effect size were used to 
compute the features most likely to explain the differences between clinical phenotypes (i.e. ILD 
record) by coupling with the features of sample sources (i.e. UCLA v.s. OUH). Our result showed 
five genera are positively associated with ILD phenotype with the effect sizes all greater than 3 
(Table 4-2). Genera Blautia and Dorea in Lachnospiraceae family have significant p-value below 
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0.001. Genera Rothia and Collinsella in Actinobacteria phylum have p-value below 0.05. We have 
found several genera that are associated with SSc-ILD phenotype.  
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Discussion 
Consistent with our prior findings128, the present study demonstrated that the SSc disease 
state is associated with alterations in the GIT microbial consortium. Using data from two 
independent SSc cohorts, we found that specific faecal microbial taxa were enriched or depleted 
among patients with SSc compared with healthy controls. We also demonstrated that specific taxa 
were associated with severity of GIT symptoms in both SSc cohorts.  
In terms of phylum-level differences, the relative abundance of Bacteroidetes was 
significantly decreased in the UCLA and OUH-SSc cohorts compared with the healthy control 
cohort. This finding is of interest in light of the recent evidence suggesting that the ratio of 
Firmicutes to Bacteroidetes may have an important effect on human health3,132. Patients with SSc 
in the UCLA cohort had the lowest proportion of Bacteroidetes (21.3%), followed by patients with 
SSc in the OUH cohort (45.0%) and healthy controls (63.2%).  
Consistent with the observed decrease in Bacteroidetes, lower level taxonomic analysis 
revealed that both SSc cohorts had significantly lower levels of the commensal genera Bacteroides, 
which is thought to protect the host from mucosal inflammation and against colonization of 
pathogenic species. Low relative abundance of Bacteroides is associated with increased disease 
activity in other chronic inflammatory diseases, such as Crohn’s disease (CD)133.The fold change 
scores for the UCLA-SSc and OUH-SSc cohorts relative to controls was nearly 5 signifying a 
substantial shift in this genus in the SSc disease state.  
Concordant with our prior study using colonic lavage specimens128,we found that 
Faecalibacterium (UCLA) and Clostridium (OUH) were also depleted in SSc. Low abundance of 
these genera is associated with increased disease activity in IBD134-136.As Clostridium species have 
been found to induce the expansion of regulatory T cells137, it is tempting to speculate that 
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depletion of these taxa may reduce the number of regulatory T cells, which may play a role in SSc 
pathogenesis138. It is important to note, however, that species within this genus vary in terms of 
their metabolic properties. Future studies may explore the relationship between the abundance of 
specific species within the Clostridium genus and levels of circulating regulatory T cells.  
In line with the potential immunoregulatory properties of Clostridium, we found that 
increased abundance of this genus was associated with decreased GIT symptoms (for the total GIT 
symptom severity score and the bloating/distension domain score). Our prior study also reported 
a link between Clostridium and GIT symptoms128. If future studies demonstrate that Clostridium 
attenuates local or systemic inflammation in SSc (through effects on T regulatory cells), therapy 
aimed at increasing the abundance or activity of species in this genus may improve SSc disease 
activity.  
In contrast, Prevotella was more abundant in patients with more severe GIT symptoms 
(bloating/distention domain, diarrhea domain scores). This genus appears to have effects on 
intestinal T helper 17 cells139, and it has been found to be increased in faecal samples from patients 
with CD102,140, and new-onset rheumatoid arthritis6. 
Also consistent with our prior study, the abundance of the pathobiont genera, 
Fusobacterium, and uncommon γ-Proteobacteria (eg, Erwinia) were higher in the UCLA-SSc 
faecal samples compared with controls. Fusobacterium species are increased in patients with CD 
compared with healthy controls and have been mechanistically proven to enhance 
proinflammatory responses16,141. 
We are intrigued by the increase of Lactobacillus in the UCLA-SSc and OUH-SSc cohorts 
compared with healthy controls. This finding has been observed now in three different SSc cohorts 
(UCLA (colonic lavage specimens, faecal specimens), OUH (faecal specimens), Swedish cohort 
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(faecal specimens))128,142. We do not attribute this expansion to probiotic use. First, due to the 
exceptionally larger scale of the intestinal microbiome, ingestion of lactobacillus-bearing 
probiotics does not measurably alter faecal microbial composition143. Second, very few patients in 
the present cohorts were taking probiotics on a regular basis, and none were taking probiotics 
within 3 weeks of the stool collection. Deemed a beneficial commensal genus by several host 
inflammatory and physiological end points in animal models, its abundance is typically reduced 
in chronic inflammatory human diseases144. We further note that members of this genus and their 
products alter the broader intestinal microbial ecosystem gene expression and function, which may 
be an intermediary of their action on systemic host phenotypes143,145. Since many patients with SSc 
consume commercial probiotic supplements that commonly include Lactobacillus species, the 
utility of Lactobacillus as a biomarker or potential intervention in patients deficient for this genus 
warrants further study.  
The overall extent of dysbiosis appeared greatest in the patients with SSc from UCLA 
compared with patients with SSc from the OUH cohort. Possible explanations for this disparity 
include different SSc phenotypes between the cohorts. For instance, more patients with SSc in the 
UCLA cohort had ILD than in the OUH cohort. Accumulating evidence suggests that GIT 
microbiota plays a central role in regulating immune responses in pulmonary disease, such as 
asthma146. It is possible that patients with SSc-ILD have distinct microbiota features compared 
with patients with SSc without ILD. Indeed, a recent analysis by Andréaasen et al142 found that 
among patients with SSc from a single-centre cohort, the extent of GIT dysbiosis was more severe 
in patients with ILD compared with patients without ILD. Furthermore, although there was a 
similar ratio of patients with diffuse versus limited cutaneous disease in each SSc cohort, there 
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may have been subtle differences in the peak severity of cutaneous sclerosis between the two 
cohorts.  
In addition to SSc disease phenotype, genetic variation may account for some of the 
observed differences in severity of dysbiosis between the two SSc cohorts. The majority of the 
OUH-SSc cohort was Caucasian with a genetic Norwegian background; whereas the UCLA cohort 
was more ethnically diverse. A study for ulcerative colitis reported that ethnicity stratifies a small 
proportion (7.5%) of observed variation in β diversity147.Dietary variation may also contribute to 
the differences observed between the two SSc cohorts.  
In contrast with a prior research142,148, faecal calprotectin concentrations were not elevated 
in the majority of patients with SSc (from the UCLA cohort), although different kits/protocols may 
have been used in prior studies. While the accumulating evidence suggests that faecal calprotectin 
is seen in inflammatory intestinal diseases (eg, IBD, colorectal cancer), future studies are needed 
to determine whether this protein is a marker of disease activity or the extent of dysbiosis in SSc.  
The findings of the present study should be considered within the context of certain 
limitations. First, the present study is cross-sectional. It is unclear whether the relationships 
observed between specific genera and GIT symptoms are causational and/or persist with time. 
Second, the sample size for both SSc cohorts is small. Despite the small sample size, we observed 
several significant associations consistent with the associations reported in our prior study128, 
suggesting that the present findings are unlikely to be due to chance alone. Third, the same healthy 
control cohort was used for the UCLA and OUH-SSc cohorts. It may have been more ideal to use 
a Norwegian healthy control cohort for the OUH-SSc analyses to control for genetic and dietary 
variation.  
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In addition, it may be prudent to include a measure of GIT transit in future SSc-GIT 
microbiome studies. This study did not assess GIT transit as there is no valid measure of GIT 
transit in SSc; however, diarrhea and constipation are intrinsically related to GIT transit. Future 
studies of this nature may consider using potential surrogate measures of GIT transit, such as 
wireless capsule endoscopy. Finally, although it is a challenge to quantify dietary patterns due to 
patient recall bias, future studies could also consider the impact of diet on microbial composition 
in SSc. Accordingly, a distinct study design will be required to assess the differential microbiota 
associated with disease state or phenotypic progression.  
The present study also has important strengths. By studying two independent SSc cohorts, 
we have minimized the risk of type 1 error that often ensues in discovery cohort analyses of this 
nature. In addition, by performing all of the sequencing analyses simultaneously, we have 
eliminated the possibility of a batch effect. We also took substantial caution to ensure that all 
patients withheld medications, such as antibiotics and probiotics, at least 3 weeks prior to the stool 
collection, by verifying medication lists three times in the month preceding the collection.  
To conclude, this study identified bacterial genera associated with SSc using sophisticated 
sequencing analyses of faecal specimens. Many of the genus-level gains and losses appreciated in 
the faecal specimens examined in the present study were also observed in our prior study using 
colonic-mucosal specimens from the same patients with SSc (but different control patients)128. 
Using two independent SSc cohorts, this study also uncovered relationships between specific 
genera and severity of SSc-GIT symptoms, which merit further investigation. While larger studies 
are needed to validate and expand on these findings, the present study is the first to characterize 
the lower GIT microbiota in two geographically and ethnically distinct SSc cohorts.  
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Tables and Figures 
Table 4-1. Systemic sclerosis (SSc) participant characteristics 
 
UCLA-SSc participants 
(N=17) 
OUH-SSc participants 
(N=17) 
Age (years) Median 52.1 (IR 46.6, 63.0) 60.5 (IR 46.0, 71.0) 
Female 15 (88.2%) 12 (70.6%) 
Race   
White 9 (52.9%) 16 (94.1%) 
Asian 2 (11.8%) 0 
More than one race 4 (23.5%) 0 
Other 2 (11.8%) 0 
Hispanic 6 (35.3%) 1 (5.9%) 
Diffuse cutaneous disease 6 (35.3%) 7 (41.2%) 
SSc disease duration (years) Median 6.6 (IR 2.5, 16.4) Median 7.0 (IR 1.0, 19.2) 
ANA positive 15/16 (93.8%) 17/17 (100%) 
Scl-70 positive 3/11 (27.3%) 4/17 (23.5%) 
Anti-centromere positive 5/11 (45.5%) 9 (52.9%) 
HRCT-Defined Interstitial 
Lung Disease 
12/17 (70.6%) 8/17 (47.1%) 
Current prednisone use* 3 (17.6%) 2 (11.8%) 
Current other 
immunosuppressant use † 
6 (35.3%) 2 (11.8%) 
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Current use of probiotic 
oral supplement ‡ 
3 (17.6%) 3 (17.6%) 
Current use of proton 
pump inhibitor 
10 (58.8%) 5 (29.4%) 
Gastrointestinal Tract 
(GIT) 2.0 Total Score 
Mean 0.7 (0.6) § Mean 0.6 (0.5) § 
Distension/Bloating Mean 1.5 (0.9) § Mean 1.2 (0.8) § 
Diarrhea Mean 0.4 (0.6) ¶ Mean 0.3 (0.3) ¶ 
Faecal Soilage Mean 0.5 (0.9) ¶ Mean 0.3 (0.6) ¶ 
Constipation Mean 0.7 (0.7) § Mean 0.6 (1.1) § 
Emotional Well-Being Mean 0.5 (0.7) § Mean 0.5 (0.7) § 
Social Functioning Mean 0.5 (0.5) § Mean 0.4 (0.6) ¶ 
Values are n (%), except where otherwise noted. 
* Dosages of prednisone were ≤10 mg daily. 
† Immunosuppressant medications used included mycophenolate (UCLA: N=1; OUH: N=2) and 
azathioprine (UCLA: N=2).  
‡ Probiotic used in the UCLA-SSc cohort included Culturelle (N=1), Florify (N=1), and Align 
(N=1). For the OUH-SSc cohort, patients consumed probiotic enriched sour milk products 
(N=3). Probiotics were not consumed within 3 weeks of the stool collection.  
§ Score indicates moderate symptom severity. 
¶ Score indicates mild symptom severity. 
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Table 4-2. List of bacteria genera that associated with ILD 
Genera 
the logarithm value 
of the highest mean 
among all the 
classes 
the feature is 
discriminative 
the 
logarithmic 
LDA score 
P-value 
g__Blautia 4.560723361 Y 4.200746601 0.000635892 
g__Anaerofustis 1.207918363 Y 3.756217898 0.05804888 
g__Rothia 1.32995036 Y 3.651263102 0.015062241 
g__Dorea 3.836995687 Y 3.530337979 0.003004453 
g__Collinsella 3.456704308 Y 3.181864475 0.024915323 
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Figure 4-1 
 
Figure 4-1. Significant differences in the β diversity of the SSc and healthy samples as 
demonstrated by principal coordinate analysis plots of the weighted UniFrac distance. Each dot 
represents a sample from a UCLA-SSc cohort patient (open circle) or a healthy control (closed 
circle). Each star represents a sample from a OUH-SSc cohort patient. The p values provided were 
calculated by analysis of variance using distance matrices. OUH, Oslo University Hospital; PCoA, 
principle coordinate analysis; SSc, systemic sclerosis; UCLA, University of California, Los 
Angeles.  
Control'vs'OUH: Control'vs'UCLA:
P=0.002%(R2=0.126) P=0.001%(R2=0.355)
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Figure 4-2 
 
Figure 4-2. Microbial composition at the phylum level in UCLA-SSc samples (top left), OUH-
SSc samples (top right) and healthy samples (bottom left). Legend provides colour coding specific 
to each phylum. OUH, Oslo University Hospital; SSc, systemic sclerosis; UCLA, University of 
California, Los Angeles.  
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Figure 4-3 
 
Figure 4-3. Genus-level taxa associated with UCLA-SSc cohort patients versus healthy 
participants. LefSe multivariate analysis was used to identify significant associations (q<0.1), and 
LDA was used to calculate the effect size for these associations. Negative and positive effect sizes 
denote genera decreased (blue) or increased (red) in patients with SSc, respectively. All genera 
with an absolute LDA score >2.5 were included in this figure. LDA, linear discriminant analysis; 
LefSe, linear discriminant analysis effect size; SSc, systemic sclerosis; UCLA, University of 
California, Los Angeles.  
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Figure 4-4 
 
 
Figure 4-4. Genus-level taxa associated with OUH-SSc cohort patients versus healthy participants. 
LefSe multivariate analysis was used to identify significant associations (q<0.1), and LDA was 
used to calculate the effect size for these associations. Negative and positive effect sizes denote 
genera decreased (blue) or increased (red) in patients with SSc, respectively. All genera with an 
absolute LDA score >2.5 were included in this figure. LDA, linear discriminant analysis; LefSe, 
linear discriminant analysis effect size; OUH, Oslo University Hospital; SSc, systemic sclerosis.  
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Figure 4-5 
 
Figure 4-5. Bacterial taxa associated with GIT disease score and domains. Patients were 
dichotomised into low (none-to-mild) or high (moderate to severe) disease severity groups for the 
total GIT 2.0 score and its individual domains (constipation, diarrhoea or distension/bloating). 
DESeq2 multivariate analysis was used to identify microbial taxa significantly associated with low 
versus high groups (Table S4-1), and calculate the fold change between groups. Negative fold 
change scores (log2) denote organisms decreased in high disease severity groups; whereas, 
positive fold change scores denote organisms increased in high disease severity groups. Legend 
provides colour code of bacterial taxa at the phylum level; ‘f” denotes family-level taxa. The size 
of the coloured dots represents the square root of the absolute mean counts of the OTUs at the 
genus level. DESeq2, differential expression analysis for sequence count data; GIT, 
gastrointestinal tract; OUT, operational taxonomic unit.  
 
Log2%FC%(Severe/None)
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Supplementary Tables and Figures 
Table S4-1. Genera associated with GIT 2.0 total score and individual domains  
Organism  Group  Fold change q value 
Actinomyces  Total GIT score, High  -1.618 0.025 
Ruminococcus  Total GIT score, High Constipation, High 
-1.758          
-2.107 
0.023      
0.003 
Dorea  Total GIT score, High  -1.239 0.092 
Parabacteroides  Constipation, High Distention/bloating, High  
-1.838                  
-1.744 
0.021      
0.057 
Undefined genus from 
Enterobacteriaceae family  Constipation, High  -1.887 0.036 
Prevotella  Diarrhea, High Distention/bloating, High  
-3.671         
-2.472 
<0.0001  
0.025 
Sutterella  Distention/bloating, High  -2.278 0.024 
SMB53 from the 
Clostridiaceae family  Distention/bloating, Low  2.101 0.025 
Blautia  Total GIT score, Low  1.648 0.025 
Clostridium  Total GIT score, Low Distension/bloating, Low 
1.329   
2.104 
0.092      
0.024 
Lactobacillus  Constipation, Low  2.505 0.003 
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Figure S4-1 
 
Figure S4-1. Alpha diversity of UCLA-SSc (blue line) and healthy (red line) samples. There were 
no significant differences in any of the alpha diversity metrics between the UCLA-SSc and healthy 
control samples based on the following metrics: phylogenetic diversity (p=0.330); observed 
species (p=0.528); Shannon index (p=0.958); and Chao 1 diversity metric (p=0.657).  
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Figure S4-2 
 
Figure S4-2. Alpha diversity of OUH-SSc (blue line) and healthy samples (red line). There were 
no significant differences in any of the alpha diversity metrics between the OUH-SSc and healthy 
control samples by the following metrics: phylogenetic diversity (p=0.078); observed species 
(p=0.206); Shannon index (p=0.265); and Chao 1 diversity metric (p=0.245)  
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Figure S4-3 
 
Figure S4-3. Alpha diversity of UCLA-SSc (blue line) and OUH-SSc (red line) samples. There 
were no significant differences in any of the alpha diversity metrics between the UCLA or OUH-
SSc samples by the following metrics: phylogenetic diversity (p=0.542); observed species 
(p=0.680); Shannon index (p=0.381); and Chao 1 diversity metric (p=0.674).  
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CHAPTER 5  
Conclusion 
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The study for host-microbiome interaction is beginning to move from association towards 
causality, that enables the prediction and testing of mechanisms by which the microbiome affects 
disease biology. In this thesis, we established a system biology screening to investigate the 
causal microbial factors regulating local chronic inflammatory disorder, CD, and explored the 
association of microbial taxa with the disease features in a systemic autoimmune disorder, SSc. 
In this conclusion, we reiterate the important observations, and consider the potential follow-up 
studies and implications.  
T cell energy metabolisms affected by metabolites 
In Chapter 2, we emphasized the importance of environmental metabolic cues to modulate 
the differentiation and activation of specific subsets of CD4+ T cells. This observation can be a 
critical mechanism to explain the recently discovered phenomenon that the environmental and 
microbial factors influence the cytokine production capacity149-151. We believed the other 
identified bioactive metabolites in this study could potentially regulate T cell intracellular 
metabolisms (Table 5-1). Additional investigation is required to identify the mechanisms.  
Three identified bioactive metabolites, HMG-CoA, mevalonate, and isopentenyl 
diphosphate are the essential intermediates in an overlapping metabolic pathway, mevalonate 
metabolism, which suggested the potential role of this pathway in T cell activation or Th17 
differentiation152. However, we found the divergent biological effects among the three molecules: 
HMG-CoA(pan-inhibition), mevalonate(pan-inhibition), and isopentenyl diphosphate (selective 
enhancement on IL-17A and IL-17F), indicating the potential involvement of multiple 
regulations. Interestingly, TCR stimulation is reported to induce expression of genes encoding 
HMG-CoA synthase and HMG-CoA reductase153, the enzymes to facilitate the production of 
HMG-CoA and mevalonate, respectively. How the activities of these enzymes be regulated by 
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the levels of HMG-CoA and mevalonate in cell cultures can be the important follow-up question. 
Future experimentation involving the blockade of these enzymes using chemical inhibitors or 
genetic manipulations can be used to assess T cells or Th17 functions. In addition, isopentenyl 
diphosphate is the first isoprenoids, the precursors of steroid, in mevalonate-cholesterol 
biosynthesis pathway. It is required to understand how the levels of isopentenyl diphosphate in 
T cell culture affects the intracellular sterol availability, which may be mediated by liver X 
receptors (LXRs)154 or the transcription factors, the sterol regulatory element-binding proteins 
(SREBPs)155 to further elucidate the mechanism of action on how isopentenyl diphosphate 
regulates CD4+ T cell function. Furthermore, isopentenyl diphosphate is also believed to be the 
agonist of human gd T cells. The approach to investigate the level and activity of the primate-
specific Vg9Vd2 T cells, is required to test the hypothesis whether isopentenyl diphosphate 
enhances the production of IL-17A and IL-17F via the activation of Vg9Vd2 T cells. 
The production of microbial metabolites 
Our metagenomics analyses yielded a substantial successful prediction rate for CD-
associated microbial metabolites with relevant T cell bioactivity. Based on our ascorbate study, 
the design was to search the metabolite producing genera based on their orthologue genomic 
contents, and direct culture of candidate isolates to validate production of metabolites. The 
detecting approach afforded an a priori selection for the targeted metabolomics approach which 
requires a customized optimization of MS parameters for each metabolite of interest. However, 
it should be emphasized that it remains challenging for the metabolomics detection from the 
bacteria-cultured samples. The first difficulty is the sample preparation to remove matrix effects 
from culture media (i.e. salts or cell debris) which could dramatically impact downstream liquid 
chromatography mass spectrometry (LC-MS) results156. Even if some extraction methods have 
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been developed (for example solid-phase or liquid-liquid extraction157), the time-consuming 
steps of extraction can potentially suppress the signals, especially for the unstable, reactive 
metabolites. The second challenge is the unknown regulation of metabolite production in 
microbes. Many genes are expressed only under specific circumstances. The optimal production 
of microbial metabolites can only achieve when the culture condition fulfills the requirements. 
A precise and refined genomic sequencing for the bacterial gene cluster in candidate organisms 
may permit the prediction of operon features for gene regulation and that could be targeted for 
culture condition evaluation.   
To prove the presence of metabolites at the local gut region, several untargeted 
metabolomics approaches have been developed158,159. However, the major challenge to the field 
is to determine whether a gut metabolite is the product of host, food, or microbiota. It is required 
to develop the culture-independent high-throughput shotgun sequencing approaches for 
measuring levels of mRNA (metatranscriptomics160) or proteins (metaproteomics161,162), which 
can uncover the production of metabolites generated from microbes and enable the functional 
assessment of disease-associated features that metagenomics studies overlook.  
The alterations of gut microbiota in SSc 
To explore the potential roles of gut microbiota in systemic autoimmune disorders, we 
studied the association of gut microbiome with systemic sclerosis. The alteration of gut microbial 
composition in SSc has been characterized in our group128,163 and other studies142,164 (Table 5-2). 
We observed the decreased abundances of genera Faecalibacterium (UCLA cohort), 
Clostridium (OUH cohort), and Bacteroides (both cohorts) in SSc patients, and the augmented 
abundances of genera Lactobacillus (both cohorts), Fusobacterium (UCLA cohort), and 
Ruminococcus (UCLA cohort). Interestingly, Ruminococcus in both studies was found to be 
 112 
largely enriched (LDA score > 3) in SSc patients. This genus was recently associated with a 
stricturing (fibrotic) complications in a multicenter inception cohort of pediatric CD study165, 
suggesting that the genus Ruminococcus could potentially perpetuate the generation of fibrotic 
tissues. Additional study is required to address causality. 
The finding of the increased abundance of the genus Lactobacillus in SSc patients was 
remarkable. Both the colonic lavage samples from the cecum and sigmoid regions and the faecal 
samples in UCLA cohort demonstrated the increase of Lactobacillus in SSc patients. This 
observation has been appreciated in three other SSc cohorts in which faecal samples were 
analyzed: Norwegian cohort163; Swedish cohort142; and Italian cohort164. This is contradicting to 
current knowledge that the abundance of Lactobacillus genus is typically reduced in chronic 
inflammatory states144 and several Lactobacillus spp. are beneficial bacteria with anti-
inflammatory effects in several animal models166,167. Studies in probiotics suggested that 
Lactobacillus reuteri reduced the colon motility via affecting enteric neuron168,169.  The reduction 
of colonic motility can lead to diminished peristalsis, which is a common feature of SSc. Future 
studies are required to determine whether members of the Lactobacillus spp. are concurrent or 
causative in SSc. 
The aforementioned studies are essential to establish the knowledge foundation for the 
transition of association to causality in the field of the microbiome, and the additional 
mechanistic validations (i.e. the in vivo model) should be pursued with the combined effort in 
basic and translational scientific community. 
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Table 
Table 5-1. Information for bioactive microbial metabolites 
Metabolite Name Category (HMDB) Pathway HMDB (conc. in bloodstream) 
(S)-3-Hydroxy-3-
methylglutaryl-CoA Fatty Acyls 
Mevalonate 
metabolism N.A. 
Hexanoyl-CoA Fatty Acyls 
Fatty acids 
biosynthesis and 
oxidation; 
ceramide 
formation 
N.A. 
GDP-mannose Purine nucleotides 
Production of 
fucosylated 
oligosaccharides 
N.A. 
Isopentenyl diphosphate Prenol lipids Mevalonate metabolism N.A. 
CoA Purine nucleotides 
Fatty acids 
biosynthesis and 
oxidation 
N.A. 
L-Glutamate Amino acids, peptides  and analogues 
Amino acid 
metabolism 8-97.4 uM 
L-Ascorbate Furanones Vitamin C metabolism 14.0-125uM 
L-Homocysteine Carboxylic acids and derivatives 
Methionine 
metabolism 2.74-10.4 uM 
(R)-Mevalonate Fatty acids and conjugates Mevalonate metabolism N.A. 
Glutaryl-CoA Fatty Acyls 
Fatty acids 
biosynthesis and 
oxidation 
N.A. 
Pyridoxine phosphate Pyridines and derivatives Vitamin B6  metabolism 0.0-0.01 uM 
Oleic acid Fatty Acid (MUFA) 
Fatty acids 
biosynthesis and 
oxidation 
11-122 uM 
Arachidonic acid Fatty Acid (PUFA) 
Fatty acids 
biosynthesis and 
oxidation 
5-55.4 uM 
Linoleic acid Fatty Acid (PUFA) 
Fatty acids 
biosynthesis and 
oxidation 
14.7-207.9uM 
Butyric acid Fatty Acid (SCFA) 
Fatty acids 
biosynthesis and 
oxidation 
1.0 (0.3- 1.5) uM 
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Table 5-2. Increased and decreased microbial taxa in SSc patients versus controls. 
 
Study Region Design/Sample N Increased in SSc* Decreased in SSc* 
Andréasson et al. 
2016 
Lund, 
Sweden 
Cross-sectional/ 
Fecal sample 98 Lactobacillus 
Faecalibacterium 
prausnitzii; 
Clostridiaceae(f) 
Volkmann et al. 2016 
Los 
Angeles, 
USA 
Cross-sectional/ 
Colonic lavage 
sample 
17† 
 
Lactobacillus; 
Bifidobacterium; 
Fusobacterium; 
Erwinia; 
Ruminococcus 
Prevotella 
Faecalibacterium; 
Clostridium; 
Rikenella 
Volkmann et al. 2017 
Oslo, 
Norway 
Cross-sectional/ 
Fecal sample 17 Lactobacillus 
Clostridium; 
Bacteroides 
Los 
Angeles, 
USA 
Cross-sectional/ 
Fecal sample 17
† 
Lactobacillus; 
Fusobacterium; 
Erwinia; 
Ruminococcus 
Faecalibacterium; 
Bacteroides 
Bosello et al. 2016 
(abstract) 
Rome, 
Italy 
Cross-sectional/ 
Fecal sample 66 
Lactobacillus; 
Ruminococcus; 
Roseburia; 
Faecalibacterium 
Clostridium; 
Odoribacter; 
Veillonella; 
Prevotella 
* Relative to healthy controls. 
† These are the same subjects. In Volkmann et al. 2016, we collected lavage specimens from the cecum and sigmoid 
colon during colonoscopy; in Volkmann et al. 2017, we collected fecal specimens. The healthy control groups were 
comprised of different individuals in the two studies. 
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